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ABSTRACT: Profiling of the kinase-binding capabilities of an
aminopyrimidine analogue detected in a cellular screen of the
St. Jude small-molecule collection led to the identification of a
novel series of FMS-like tyrosine kinase 3 (FLT3) inhibitors.
Structure−activity relationship studies led to the development
of compounds exhibiting good potency against MV4-11 and
MOLM13 acute myelogenous leukemia cells driven by FLT3,
regardless of their FLT3 mutation status. In vitro pharmaco-
logical profiling demonstrated that compound 5e shows characteristics suitable for further preclinical development.
■ INTRODUCTION
Acute myelogenous leukemia (AML) is characterized by
malignant proliferation of hematopoietic cells in the bone
marrow, leading to overproduction of abnormally functioning
white blood cells. This situation leads to decreased production of
red blood cells, infection, and dysfunction of organs. AML occurs
in roughly 4 per 100 000 individuals; more than half of the
reported cases occur in individuals over 65 years of age.1
Although the use of hematopoietic stem cell transplants has
provided some improved clinical outcomes in AML patients,
there has been very little improvement in patient prognosis over
the past 20 years.2
Normal functioning of FMS-like tyrosine kinase 3 (FLT3), a
type III receptor tyrosine kinase, is important for the develop-
ment and proliferation of hematopoietic stem cells.3,4 The
binding of the FLT3 ligand to this transmembrane protein causes
dimerization and subsequent FLT3 autophosphorylation, which
then triggers the activation of several signaling cascades,
including the RAS, SRC, and STAT5 pathways.5−8 Constitutive
activation of FLT3 leads to dysregulated cellular proliferation of
hematopoietic cells, and nearly one-third of AML patients have
mutations in the FLT3 gene.9 Two classes of mutations are
commonly found in FLT3: an internal tandem duplication
(ITD) located in the juxtamembrane domain, which is the most
common, and point mutations at or near residue Asp835.10−14
Typically, an AML patient’s prognosis is worse if he/she
possesses the FLT3-ITD mutation compared to that for patients
having normal levels of wild-type FLT3 (wt-FLT3).15,16
Initially, kinase inhibitors developed for solid tumors were
investigated as FLT3 inhibitors. Several of these inhibitors,
including midostaurin,17−19 lestaurtinib,20−22 crenolanib,23−26
tandutinib,27−29 sunitinib,30−32 and sorafenib,33−36 have been
evaluated in clinical trials. These compounds tended to inhibit
multiple tyrosine kinases, thus leading to toxicity due to off-target
effects.37 Subsequently, quizartinib and crenolanib were
developed as more selective FLT3 inhibitors.38−42 The clinical
response to FLT3 inhibitors often persists only for a short
duration, with acquired point mutations in FLT3 that impact the
binding of the inhibitors driving the limited response.37,43,44 In
particular, FLT3 Asp835 mutants tend to be resistant to “type II”
kinase inhibitors that bind to an inactive conformation of the
enzyme, wherein the inhibitor is able to make contacts within an
allosteric pocket adjacent to the ATP site due to the Asp-Phe-Gly
(DFG) motif in the activation loop adopting a conformation in
which it is flipped out relative to its active conformation.45−48
However, treatment with different FLT3 inhibitors can lead to
alternate sets of acquired mutations, and some “type I” ATP-
pocket-binding inhibitors, which bind within the ATP site but do
not reach into the allosteric pocket and do not rely on specific
DFG motif conformations, such as crenolanib, are able to bind
selectively to FLT3 and also retain their activity against FLT3
Asp835 mutants.23,49,50 Consequently, the development of
additional new FLT3 inhibitors that can retain their activity
against commonly acquired mutations or the use of FLT3
inhibitors in combination therapies may be potential methods to
circumvent the problem of resistance.
While investigating potential compounds of interest identified
during a cellular high-throughput phenotypic screen for a brain
tumor project (results not yet published), the kinase-binding
profile of one of the hits suggested potential use as a FLT3
Received: February 8, 2017
Accepted: April 19, 2017
Published: May 10, 2017
Article
http://pubs.acs.org/journal/acsodf
© 2017 American Chemical Society 1985 DOI: 10.1021/acsomega.7b00144
ACS Omega 2017, 2, 1985−2009
This is an open access article published under an ACS AuthorChoice License, which permits
copying and redistribution of the article or any adaptations for non-commercial purposes.
inhibitor. We therefore synthesized a series of compounds based
on this hit for evaluation against FLT3 and investigation of their
activities in AML cell lines. Herein we describe the structure−
activity (SAR) and structure−property relationships resulting
from this series of molecules.
■ RESULTS AND DISCUSSION
Preliminary Profiling of the Hit (1). The kinase-binding
profile of 1 was evaluated using the DiscoveRx KINOMEscan
panel of 468 kinases, with ligand competition beingmeasured at a
single inhibitor concentration of 1 (10 μM).51−53 Selectivity was
evaluated through a comparison of the number of nonmutant
kinases with which 1 interacted relative to the total number of
nonmutant kinases tested. Compound 1 reduced ligand binding
by >90% for 31 kinases of 403 nonmutant kinases tested. Within
that set, seven had activity reduced to >99% of that of the control.
As depicted in Figure 1, 1 bound with the highest affinity to
kinases in the tyrosine kinase family. Further information on the
kinase-binding profile is found in Table S1. Subsequently, the Kd
values were determined for kinases in which compound 1 had
blocked the binding of ligand by >90%, revealing that 1 bound
with a high affinity to FLT3 (61 nM) and a significant but lower
affinity to PDGFRB, the JAK1 JH2 domain, and JAK2 JH1
domain (Table 1). Eleven of the kinases had binding affinities
within tenfold of those for the FLT3 primary target, which is a
reasonably selective binding profile. For instance, previously
studied kinase inhibitors, such as the AKT1 inhibitor GSK-
690693, the IGF1R inhibitor GSK-1838705A, and the
mammalian target of rapamycin inhibitor PP-242, had similar
relative selectivity profiles.54 We also verified that compound 1
inhibited the enzymatic activity of FLT3. As measured using the
Z′LYTE kinase inhibition assay (ThermoFisher), 1 was a potent
inhibitor of the FLT3WT enzyme (IC50 = 32 nM; 95% confidence
interval (CI 95), 24−43 nM).55 Compound 1 was also a
reasonably potent inhibitor of proliferation for the well-
characterized MV4-11 AML cell line, which carries an FLT3-
ITD mutation (EC50 = 320 nM; CI 95, 160−650 nM). This
finding suggested that 1 acts on FLT3-ITD in these cells.
Although aminopyrimidines have been well studied as kinase
inhibitors, low-molecular-weight structures that include an
aliphatic moiety, such as 1, are not as widely reported and, to
the best of our knowledge, have not been described specifically as
FLT3 kinase inhibitors.56,57 Taken together, the promising
activity profile and fairly novel structural character of 1 prompted
us to explore additional SARs.
Chemistry.We developed a general route for the synthesis of
the majority of the compounds discussed herein (Scheme 1) on
the basis of prior work on Aurora kinase inhibitors.58 The route,
which relied upon sequential additions of an aliphatic amine and
various anilines to 2,4-dichloropyrimidine, facilitated systematic
variation of the amine substituents at the 2- and 4-positions of the
pyrimidine ring. Whereas the first substitution using an aliphatic
amine typically proceeded facilely at either 0 °C or room
temperature (rt), subsequent reactions with the anilines required
increased temperature and catalytic HCl. Anilines were obtained
either from commercial vendors or were synthesized via the
Suzuki reaction or other known procedures (Schemes S1−
S6).59,60 To help define the minimal pharmacophore, we
investigated the impact of removing nitrogen atoms from the
scaffold. Pyridine analogues were synthesized by the routes
shown in Schemes 2 and 3. These involved nucleophilic addition
of cyclohexylamine to the halopyrimidine, followed by a
palladium-catalyzed coupling reaction to install the 3-pyridinyl-
3-ylaniline functional group. Schemes 4−7 depict the routes used
to synthesize analogues in which the amine linkers at the 2- and/
or 4-positions of the aminopyrimidine were replaced with N-
methyl or oxygen. N-Methylcyclohexane was installed at the 2-
position by treating with triethylamine (Scheme 4), whereas
cyclohexanol was incorporated by reacting with 2,4-dichloropyr-
imidine in the presence of sodium hydride (Scheme 5).
Substituents at the 4-position were installed using catalytic
HCl and by refluxing in ethanol (EtOH) (Schemes 4−7).
Overall, the routes proceeded with sufficient yield (3−85%
yield), producing all targeted analogues for characterization,
although, undoubtedly, further optimization could be beneficial
for individual analogues. All compounds used for subsequent
testing were purified to greater than 95% purity, as confirmed by
the combination of liquid chromatography−mass spectrometry
(LC−MS) and 1H NMR studies.
SAR.We utilized the FLT3WT enzyme assay to determine the
potencies of all analogues of 1made during this study (Table S2).
In parallel, we tested the effects on the proliferation of MV4-11
cells (Table S2). We also measured the effects of these
compounds on the proliferation of untransformed BJ fibroblasts
to evaluate the dependency of cellular effects upon the presence
of a driving FLT3 mutation (Table S3). Because cellular assays
include fetal bovine serum within the media, there is a potential
that the EC50 values could differ from the actual values due to
plasma protein binding.61 The solubility and permeability as well
as the potential susceptibility to P-glycoprotein (PGP) efflux
were assessed for selected compounds (Tables S4 and S5) to aid
in interpreting the data and planning for structural modifications.
The initial focus of the project was defining the minimal
pharmacophore for the inhibitors. Replacement of the nitrogen
at the 1-position with a carbon atom (9) did not have a large
impact on potency for kinase inhibition but completely ablated
effects upon proliferation of MV4-11 cells (Table 2). Removal of
the nitrogen at the 3-position (13) reduced the potency of kinase
inhibition compared to that of 1, while adding weak
antiproliferative effects on untransformed BJ cells (Table S3).
Figure 1. Lead series analogue 1. (a) Structure of 1. (b) Kinase profiling
of 1. Kinase tree image showing relative inhibition of ligand binding to
468 human kinases, with the size of the circle being proportionate to the
% inhibition at a fixed dose of 10 μM.
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Compound 14, in which the location of the ring nitrogen had
shifted, exhibited good enzymatic inhibitory potency but lacked
MV4-11 cellular activity and also was weakly active against BJ
fibroblasts (Table S3). Therefore, the pyrimidine core was
necessary for optimal activity.
We examined the effects of replacing the linker atoms on both
FLT3 inhibition and MV4-11 proliferation using both N-methyl
and ether replacements (Table 3). Although replacement of the
2-amine withN-methyl abrogated activity against FLT3 (21, 17),
17 possessed modest cellular potency, which might be due to
metabolic removal of the methyl groups (unexplored).
Replacement of the amine linkers with ethers at either the 4-
position (19) or both the 2- and 4-position (20) did not greatly
impact the enzymatic activity, whereas replacement of only the 2-
nitrogen with an ether linkage did reduce the enzymatic activity
nearly 40-fold compared to that of 1 (22). However, compounds
19, 22, and 20 were all devoid of effects on MV4-11 cell
proliferation. Although the lack of enzymatic inhibition exhibited
by N-methylated compounds 17 and 21 could suggest that a key
hydrogen-bonding interaction may be made with FLT3 through
the amine at the 2-position, compound 20, which contains an
ether at this location, also demonstrated potent FLT3 inhibition.
Therefore, it is not clear what particular interactions occur
between these compounds and the kinase. Overall, however, the
inclusion of amine linkers at the 2- and 4-position provided the
best combination of enzymatic and cellular activity. On the basis
of these results, we focused on the 2,4-aminopyrimidine scaffold
for further optimization.
Next, we explored the replacement of the pendent hydro-
phobic groups surrounding the aminopyrimidine scaffold. First,
the cyclohexyl substituent at the 4-position was fixed, while the
substituent at the 2-position was systematically varied (Table 4).
Paring the structure down by removing the pyridine ring (4a)
caused a reduction in FLT3 inhibitory activity and ablated
activity in MV4-11 cells; therefore, this functional group may
improve binding to FLT3 through a potential a H-bonding
interaction. Reductions in FLT3 inhibition and MV4-11 cellular
activity were also observed with compounds 4c−f, which also did
not contain the pyridine ring in 1. Replacement of the 3-(pyridin-
3-yl)aniline moiety with either 2- or 3-substituted biphenyl (4b,
4g) abolished all activity. Incorporation of a 3′-methoxybiphenyl
(4i) or methyl ester (4j) led to a reduction in enzymatic and
MV4-11 cellular activities compared to those of 1, and these
compounds also gained weak activity against BJ cells (Table S3).
Shifting the location of the ring nitrogen (4h) reduced the
activity compared to that of 1. However, replacement of the 3-
Table 1. Kd Values for 1
kinase Kd (nM)
a kinase Kd (nM)
a
ABL1 (H396P)-phosphorylated 2100 LCK 2900
AURKA 1600 MERTK 2800
AURKC >10 000 MINK 2500
AXL 2100 NEK10 410
BLK 3900 PDGFRB 120
CLK1 430 PIK4CB 370
CLK4 690 PIP5K1C 610
CSF1R 590 PRKCQ 1600
CSF1R-autoinhibited 1500 PRKD3 1700
EPHB6 560 RET (M918T) 1200
FLT3 61 RET (V804M) 1400
HCK 2100 RSK1 (Kin.Dom.1-N-terminal) 4400
IRAK1 1500 SRC 1100
IRAK3 1400 TRKA 1100
JAK1 (JH2 domain-pseudokinase) 290 TYK2 (JH1 domain-catalytic) 350
JAK2 (JH1 domain-catalytic) 260 TYK2 (JH2 domain-pseudokinase) 740
JAK3 (JH1 domain-catalytic) 1300 TYRO3 2700
KIT 1500
aKd values are reported as the mean of two experiments.
Scheme 1. General Route for the Synthesis of 2,4-
Aminopyrimidine Analoguesa
aReagents and conditions: (a) NH2-R1, dichloromethane (DCM) or
methanol (MeOH) or NH2−R1, triethylamine, DCM, rt, 5−16 h, 1−
60%; (b) NH2-R2, catalytic HCl, EtOH or MeOH, reflux, 1−22 h, 3−
85%.
Scheme 2. Synthesis of Compound 9a
aReagents and conditions: (a) aminocyclohexane, triethylamine, N-methyl-2-pyrrolidone (NMP), 100 °C, 21 h, 10%; (b) 3-pyridinyl-3-ylaniline,
Pd2(dba)3, R-BINAP, sodium tert-butoxide, toluene, 80 °C, 16 h, 56%.
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pyridinyl group with other nitrogen-containing heterocycles was
tolerated by FLT3 (4k−n), further suggesting that a nitrogen
atom in this positionmay provide critical interactions with FLT3.
Compounds 4o, 4p, and 4r, which also lacked a pyridinyl
nitrogen, showed diminished FLT3 inhibition compared to that
by 1 as well. Although compound 4q contained the desired
pyridine ring, altered molecular conformations may have led to
this compound’s lack of activity. Compound 4s also exhibited
good activity, suggesting that the carboxamidemoietymay be in a
beneficial location for hydrogen-bonding interactions with
FLT3. Inclusion of a pyridine ring at the para position (4t)
provided modest FLT3 activity but good MV4-11 cellular
Scheme 3. Synthesis of Compounds 13 and 14a
aReagents and conditions: (a) aminocyclohexane, triethylamine, NMP, 80 °C, 16 h, 15% 11, 2% 12; (b) 3-pyridinyl-3-ylaniline, Pd2(dba)3, R-
BINAP, sodium tert-butoxide, dimethylformamide (DMF), 140 °C, 35 mW, 1 h, 24%; (c) 3-pyridinyl-3-ylaniline, Pd2(dba)3, R-BINAP, sodium tert-
butoxide, toluene, 80 °C, 16 h, 9%.
Scheme 4. Synthesis of Compounds 16 and 17a
aReagents and conditions: (a) N-methylaminocyclohexane, triethylamine, ethanol, reflux, 5 h, 59%; (b) 3-pyridinyl-3-ylaniline, catalytic HCl,
ethanol, reflux, 3 h, 25%; (c) N-methyl-3-(pyridin-3-yl)aniline, catalytic HCl, ethanol, reflux, 2 h, 27%.
Scheme 5. Synthesis of Compounds 19 and 20a
aReagents and conditions: (a) cyclohexanol, sodium hydride, DMF, 0 °C to rt, 16 h, 3%; (b) 3-pyridinyl-3-ylaniline, catalytic HCl, ethanol, reflux, 3
h, 9%; (c) 3-(pyridin-3-yl)phenol, catalytic HCl, ethanol, reflux, 16 h, 52%.
Scheme 6. Synthesis of Compound 21a
aReagents and conditions: N-methyl-3-(pyridin-3-yl)aniline, catalytic
HCl, ethanol, reflux, 2 h, 6%.
Scheme 7. Synthesis of Compound 22a
aReagents and conditions: 3-(pyridin-3-yl)phenol, catalytic HCl,
ethanol, reflux, 16 h, 81%.
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activity. Although compound 4u was inactive against FLT3, an
effect on MV4-11 cell proliferation was observed. The potential
off-target kinase activity of this compound was not investigated,
but interactions with other kinases may contribute to the
moderate cellular activity of compounds 4t and 4u. Taken
together, these results point to a very strong preference for
particular steric and electronic arrangements on this portion of
the molecule, with the original 3-pyridinylphenyl presenting a
good balance of properties.
In parallel, we synthesized a series of compounds keeping the
3-pyridinyl-3-ylaniline moiety constant, while varying the
aliphatic substituents at the 4-position. Short linear, branched,
and cyclic aliphatic groups were evaluated (Table 5). Although
reduced enzymatic inhibition and a loss of MV4-11 cellular
activity was observed when replacing the cyclohexyl group with a
methyl (5a), good potency was obtained with either an ethyl
(5b) or propyl (5c) group and moderate potency was obtained
with a butyl (5d) group. Branched alkyl chains, such as isopropyl
(5e), sec-butyl (5j, 5k), and tert-butyl (5f), provided improve-
ments in the FLT3 inhibitory activity and approximately 10-fold
improvements in MV4-11 growth inhibition relative to those of
1. Inclusion of ether (5g), ester (5h), or carboxylic acid (5i)
functionalities within the branched aliphatic substituents greatly
reduced cellular activity. Although 5g had good solubility and
permeability, the lower stability of the methoxy group in the
cellular environment may have impacted its cellular activity (not
explored). Some compounds with aliphatic rings, such as 5l and
5m, demonstrated good enzymatic and cellular activities.
Although both the cyclopropyl and cyclobutyl (5n) groups
afforded good potency against the FLT3 enzyme, poor solubility
(Table S4) may have hampered the cellular activity of the latter.
Despite its low solubility, compound 5o exhibited good cellular
activity. Therefore, additional properties beyond solubility could
potentially have subtle effects on activity. Although 5q was
approximately 4-fold more potent than 1 against FLT3, the
potency against MV4-11 cells was not improved due to poor
cellular permeability (Table S4). Inclusion of a methoxy group
(5p) was not beneficial. Replacing the amine functionality in the
aliphatic ring of 5q with an ether (5r) provided only moderate
enzymatic and cellular activities.
Because of its improved activity against FLT3 and MV4-11
cells compared to that of 1, we fixed the 4-position as the
isopropyl group and varied the 2-position of the compound to
determine whether the activity trends observed would be similar
to those in the cyclohexyl series, as previously shown in Table 4.
Similar to that in the cyclohexyl series, inclusion of a methoxy
group (6e) or replacement of the pyridine functionality with a 2-,
3-, or 4-biphenyl (6a, 6c, 6m) caused decreases in both FLT3
inhibitory activity and cellular potency (Table 6). Inclusion of a
tert-butyl group in place of the pyridine ring (6b) abrogated
activity as well. Shifting the nitrogen from the 3-position to the 2-
position (6d) or the 4-position (6l) also reduced potency,
paralleling our prior observations and suggesting that a nitrogen
at the 3-position may act as an H-bond acceptor to make an
important binding interaction. Incorporation of a methyl ester
(6f) led to reduced activity. The potency was comparable to that
of 1 when the 3-pyridinyl group was replaced with a pyrazole
(6i), and inhibition of MV4-11 cell proliferation improved when
an imidazole (6j) or pyrazine (6k) replaced the pyridine.
Compounds containing oxazole (6g) or thiazole (6h) moieties,
however, provided less potent FLT3 inhibition and MV4-11
cellular activity. Similar to the effect observed with 4s, the
carboxamide-functionalized compound 6n also exhibited mod-
erate enzymatic inhibition and activity against MV4-11 cells.
On the basis of the balance of activity, we selected 5e for
further profiling. The compound retained its FLT3 potency (3.6
nM) and selectivity on the basis of profiling the Kd values for a
subset of kinases inhibited by 1 (Table 7). Despite potent
binding to PDGFRB (28 nM) and the JAK1 JH2 domain (28
nM), 5e was still approximately 8-fold more potent against
FLT3. Therefore, modifications explored during the SAR studies
did not appear to significantly affect kinase selectivity compared
to that of the initial hit compound.
In Vitro Effects against FLT3 Mutants and MOLM13
Cells. Because of the demonstrated activity of this series of
compounds in MV4-11 cells, we evaluated a subset of
compounds to determine whether they inhibited the prolifer-
ation of other FLT3 mutant AML cells. The initial hit compound
1 and 5e, 6k, and a structurally related inactive compound 6a
were tested for their ability to inhibit the proliferation of
MOLM13 cells, which also contain the FLT3-ITDmutation, and
a sorafenib-resistant progeny of MOLM13 that has acquired an
additional tyrosine kinase domain (TKD) mutation, Asp835.50
As shown in Figure 2, 6k was the most potent at inhibiting
MOLM13 cell viability (IC50 = 45 nM; CI 95, 38−55 nM),
followed by 5e (IC50 = 136 nM; CI 95, 112−164 nM). The
relative sensitivity of MOLM13 cells to 5e and 6k was correlated
to the loss of FLT3-ITD phosphorylation and downstream
STAT5 signaling, with FLT3 IC50 values estimated to be within
50−100 nM in these experiments (Figure 3). In addition, all
three tested compounds (1, 5e, and 6k) possessed similar growth
inhibitory potencies against both parental MOLM13FLT3‑ITD and
Table 2. SAR of the Aminopyrimidine Ring for Compounds 9,
13, 14, and Quizartinib







9 C N C 80 >10 000 >10 000
13 C C N 1500 >16 000 10 615
14 N C C 141 >8000 8741
quizartinib 40 0.7 >22 000
aIC50 and EC50 values are reported as the mean of triplicates. Values
for CI 95 are included in Table S3.
Table 3. SAR Analysis of Modifications to the Linkers for
Compounds 16, 17, and 19−22
compd. X Y FLT3 IC50 (nM)
a MV4-11 EC50 (nM)
a
16 N-Me NH 82 >8000
21 NH N-Me >11 000 >4000
17 N-Me N-Me >15 000 39
19 O NH 187 >6000
22 NH O 1260 >14 000
20 O O 49 >13 000
aIC50 and EC50 values are reported as the mean of triplicates. Values
for CI 95 are included in Table S3.
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progenyMOLM13FLT3‑ITD/D835Y cells. We also determined theKd
values for compounds 1, 5e, and 6a against several FLT3mutants
(Table 8).62 Compound 5e bound more tightly to all FLT3
variants tested compared with 1, whereas 6a did not bind to any
FLT3 variant at any tested concentration. Therefore, there was
very good correlation between the improved potency of 5e
against MOLM13 cells and improved binding to FLT3 variants.
Interestingly, the fold-difference in the affinities of 5e and 1 was
very similar between the FLT3 and Asp835 mutants, which is
mirrored by similar potencies in parental and kinase inhibitor-
resistant MOLM13 cells. This is a desirable profile for a new
FLT3 inhibitor scaffold. Previously studied type I kinase
inhibitors have also had similar to better affinities for FLT3,
FLT3-ITD, or activating TKD mutations, suggesting that these
Table 4. SAR of the Substituents at the Aminopyrimidine 2-Position for Compounds 1 and 4a−ua
aIC50 and EC50 values are reported as the mean of triplicates. Values for CI 95 are included in Table S3.
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compounds may have the properties of a type I inhibitor, which
binds in the ATP-binding pocket of the kinase.63 Additionally,
when selected compounds were evaluated in the Z′LYTE FLT3
kinase inhibition assay under standard conditions but using
either a lower (100 μM) or higher (2.5 mM) concentration of
ATP, shifts in the FLT3 IC50 values of these compounds were
observed. For instance, the IC50 of the initial hit, 1, was reduced
to <6 nM in the presence of 100 μM ATP and increased to 116
nM (CI 95, 70−193 nM) when the assay was conducted at a 2.5
mMATP concentration. Similar to other type I kinase inhibitors,
these compounds may make crucial binding interactions within
the ATP site and therefore may not be sensitive to the
conformation of the DFG motif.
In Vitro ADME Studies. We evaluated the in vitro
pharmacological characteristics of 1, 5e, and 6k to assess their
potential for use in in vivo studies. All three analogues had
excellent passive permeabilities (1880 ± 170 × 10−6, 2000± 190
× 10−6, and 1870± 60× 10−6 cm/s, respectively), as measured in
the PAMPA assay. Neither 1 nor 5e showed susceptibility to
PGP efflux (Table S5) in cellular permeability assays. Compound
6k was not evaluated in this assay. Although the solubility of 1 in
PBS was poor (0.4 ± 0.9 μM), that of 5e was reasonable (26.4 ±
17.0 μM). Finally, the stability of these three compounds in liver
microsomes from four species was lower than desirable (Table
9). However, the plasma stability of 5e and 6kwas excellent (>48
h). Overall, these studies would predict reasonable oral
absorption for 5e but rapid clearance (CL) for all three, and it
would be expected that first-pass metabolism effects could cause
low bioavailability.
In Vivo Pharmacokinetics. On the basis of the results from
themicrosomal stability studies of 1, 5e, and 6k, we selected 5e to
evaluate in vivo pharmacokinetics at three doses by intra-
peritoneal (i.p.) injection. A greater than proportional dose-
dependent increase in Cmax (Table 10) was observed (327, 927,
and 1625 nM for 3, 5, and 10 mg/kg respectively) and the half-
life of the compound ranged from 0.23 to 1 h, paralleling our
observations in mouse microsome models (0.2−1 h at 0.8−20
μM). The area under the concentration−time curve (AUC)
within 24 h also displayed a dose-dependent trend. CL, however,
was high at all doses tested. Therefore, because of the undesirable
pharmacokinetic profile of 5e, we did not pursue efficacy
modeling using a human AML xenograft model with this
compound because its pharmacokinetic properties could
potentially confound the results of such a study.
■ CONCLUSIONS
Starting with hit compound 1, we developed a SAR concerning
inhibition of FLT3 enzymatic activity and MV4-11 cellular
proliferation. Overall, the SAR for enzymatic inhibition and
inhibition of cellular proliferation correlated well. We found that
the pyrimidine nitrogens and nitrogen linker atoms were
important for MV4-11 cellular activity. Inclusion of a 3-
pyridinylphenyl group at the 2-position and a small aliphatic
substituent at the 4-position provided a balance of potency,
solubility, and permeability (Figure 4). Additionally, the pan-
Table 5. SAR of the Substituents at the Aminopyrimidine 4-Position for Compounds 5a−ra,b
aIC50 and EC50 values are reported as the mean of triplicates. Values for CI 95 are included in Table S3.
bOn the basis of assay conditions, IC50
values below 6 nM cannot be accurately measured.
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activity against FLT3mutations and the relatively high selectivity
for FLT3were both generally maintained during the SAR studies,
suggesting that the scaffold might provide good lead molecules
for further development. From these studies, we developed 5e,
which not only had improved potency against FLT3 andMV4-11
cells but also demonstrated activity in MOLM13 cells possessing
FLT3-ITD and FLT3 inhibitor-resistant TKD mutations.
Compound 5e possessed acceptable in vitro ADME properties
and was selected for additional preclinical studies. However,
because of its low metabolic stability and high CL in
pharmacokinetic studies, we determined that these properties
need to be improved before further preclinical studies are
undertaken. Efforts toward this goal are on-going.
■ EXPERIMENTAL SECTION
Chemistry. All chemical reagents were purchased from
commercial suppliers (Acros, Combi-Blocks, Enamine, Oak-
wood, Sigma Aldrich, Strem) and were used without further
purification. Solvents were dried using a column-exchange
system64 Thin-layer chromatography (TLC) was performed
using Merck Millipore silica gel 60G F254 glass plates and
visualized using a 254 nm UV lamp for detection. Microwave
Table 6. Additional SAR at the Aminopyrimidine 2-Position for Compounds 6a−na,b
aIC50 and EC50 values are reported as the mean of triplicates. Values for CI 95 are included in Table S3.
bOn the basis of assay conditions, IC50
values below 6 nM cannot be accurately measured.








JAK1 (JH2 domain-pseudokinase) 28





TYK2 (JH1 domain-catalytic) 740
TYK2 (JH2 domain-pseudokinase) 210
aKd values are reported as the mean of two experiments.
ACS Omega Article
DOI: 10.1021/acsomega.7b00144
ACS Omega 2017, 2, 1985−2009
1992
experiments were carried out using a Biotage Initiator system.
Automated flash chromatography was performed using the
Biotage SP1 flash column system with silica gel SNAP columns
or C18 SNAP columns for reversed-phase purifications.65 Rf
values are quoted for the eluent system stated. Evaporation was
carried out using a Büchi Rotovapor. NMR spectra were
recorded on either a Bruker 400 MHz or Bruker 500 MHz
spectrometer in the solvents indicated, and the spectra were
processed using MestReNova (8.1) referenced to the solvent
peak. Melting points were obtained using a Büchi-545. Optical
rotations were recorded using a Jasco P-1010 polarimeter at the
D line of sodium (λ, 589 nM). Purity was assessed using ultra-
performance liquid chromatography mass spectrometry
(UPLC−MS; Acquity PDA detector, Acquity SQ detector, and
Acquity UPLC BEH-C18 column, 1.7 μm, 2.1× 50mm2;Waters
Corp.). Data were acquired usingMasslynx, version 4.1. The flow
rate was 0.5 mL/min, and the gradient started with 95% A (0.1%
formic acid in H2O), changed to 95% B (0.1% formic acid in
acetonitrile), and then returned to 95% A. The mass
spectrometer was operated in the positive-ion mode with
electrospray ionization. Verification of enantiopurity was
conducted using supercritical fluid chromatography with a
Chiralcel OD-H (4.6 × 250 mm2) or Chiralcel AD-H (4.6 ×
250 mm2) column. The compounds were purified to ≥95%
purity and assessed using LC/MS by UV/evaporative light
scattering detector detection, unless stated otherwise, and
efficacy data were obtained only on compounds that were
≥95% pure.
2-Chloro-N-cyclohexylpyrimidin-4-amine (3a). To a sus-
pension of 2,4-dichloropyrimidine 2 (10 mmol, 1.0 equiv) in
DCM (20 mL, 0.50 M) under a nitrogen atmosphere was added
cyclohexylamine (20mmol, 2.0 equiv) at rt. After stirring for 16 h
at rt, the reaction mixture was concentrated and purified directly
using automated flash chromatography (ethyl acetate (EtOAc)/
hexanes), followed by evaporation, giving 3a as a white solid (1.2
g, 57%). TLC Rf 0.30 (30% EtOAc/hexanes). LC−MS (ESI)m/
z: 214 [M + H]+. 1H NMR (500 MHz, CDCl3) δ 8.02 (s, 1H),
6.22 (d, J = 6.0 Hz, 1H), 5.20 (br s, 1H), 3.42 (br s, 1H), 2.08−
1.93 (m, 2H), 1.77 (dt, J = 13.6, 4.0 Hz, 2H), 1.67 (dt, J = 12.9,
4.1 Hz, 1H), 1.38−1.44 (m, 2H), 1.32−1.13 (m, 3H). 13C NMR
(126 MHz, CDCl3) δ 162.76, 160.83, 157.41, 100.54, 50.12,
32.68, 25.37, 24.51.
N4-Cyclohexyl-N2-(3-(pyridin-3-yl)phenyl)pyrimidine-2,4-
diamine (1). To a mixture of 3a (0.10 mmol, 1.0 equiv) in EtOH
(0.50 mL, 0.20 M) under a nitrogen atmosphere at rt were added
3-(pyridin-3-yl)aniline (0.11 mmol, 1.1 equiv) and a drop of 1 N
HCl. The reaction mixture was heated to reflux and stirred at that
temperature for 3 h; it was then cooled to rt. Purification using
automated flash chromatography (MeOH/DCM) was followed
by evaporation, giving 1 as a white film (0.002 g, 6%). TLC Rf 0.5
(10% MeOH/DCM). LC−MS (ESI) m/z: 346 [M + H]+. 1H
NMR (500 MHz, MeOD) δ 8.90−8.75 (s, 1H), 8.54 (d, J = 5.0
Hz, 1H), 8.11 (dt, J = 7.8, 2.0 Hz, 2H), 7.73 (s, 1H), 7.64 (d, J =
10 Hz, 1H), 7.54 (dd, J = 7.9, 4.9 Hz, 1H), 7.41 (t, J = 7.9 Hz,
1H), 7.25 (d, J = 10 Hz, 1H), 5.95 (d, J = 6.0 Hz, 1H), 3.84 (br s,
Figure 2. Relative inhibition of the proliferation of MOLM13 cells carrying either FLT3-ITD or FLT3-ITD with an additional mutation of D835Y by
compounds 1, 5e, 6k, and 6a, as evaluated in the MTT assay. Data are expressed as the mean of cell viability measurements ± SE of three experiments,
with six replicates each (n = 18), after treatment with drug for 72 h. (IC50 and CI 95 in nM: MOLM13
FLT3‑ITD_1 = 620, 461−833;
MOLM13FLT3‑ITD/D835Y_1 = 1153, 869−1604; MOLM13FLT3‑ITD_5e = 136, 112−164; MOLM13FLT3‑ITD/D835Y_5e = 82, 66−103; MOLM13FLT3‑ITD_6k
= 45, 38−55; MOLM13FLT3‑ITD/D835Y_6k = 77, 63−94; MOLM13FLT3‑ITD_6a = >10 000; MOLM13FLT3‑ITD/D835Y_6a = 4260, 3060−5930.)
Figure 3. Inhibition of FLT3 signaling by compounds 5e and 6k.
MOLM13FLT3‑ITD cells were treated for 1 h with dimethyl sulfoxide
(DMSO) or increasing concentrations of (A) compound 5e or (B)
compound 6k and lysed. Western blot analysis was performed on the
FLT3 immunoprecipitation eluent or the whole-cell lysate using the
indicated antibodies.
Table 8. Kd Values for 1, 5e, and 6a Bound to Mutant FLT3
Kinases
kinase 1 Kd (nM)
a 5e Kd (nM)
a 6a Kd (nM)
a
FLT3 61 3.6 >10 000
FLT3 (D835H) 22 1.2 >10 000
FLT3 (D835V) 7.7 0.8 >10 000
FLT3 (D835Y) 13 0.59 >10 000
FLT3 (ITD) 31 1.4 >10 000
FLT3 (ITD, D835V) 7.2 0.36 >10 000
FLT3 (ITD, F691L) 270 11 >10 000
FLT3 (K663Q) 110 13 >10 000
FLT3 (N841I) 48 11 >10 000
FLT3 (R834Q) 680 82 >10 000
FLT3-autoinhibited 1100 78 >10 000
aKd values are reported as the mean of two experiments.
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1H), 1.98 (dd, J = 9.4, 4.8 Hz, 2H), 1.67−1.69 (m, 2H), 1.56 (s,
1H), 1.28−1.06 (m, 5H). 13C NMR (126 MHz, MeOD) δ
162.32, 159.48, 153.10, 147.23, 147.10, 141.42, 137.93, 137.65,
135.32, 128.98, 124.06, 120.04, 119.00, 117.79, 97.65, 49.23,
32.43, 25.34, 24.72.
6-Bromo-N-cyclohexylpyridin-2-amine (8).Amixture of 2,6-
dibromopyridine 7 (1.0 mmol, 1.0 equiv), cyclohexylamine (1.6
mmol, 1.6 equiv), and triethylamine (1.2 mmol, 1.2 equiv) was
stirred at 100 °C in NMP (1.0 mL, 1.0 M) under a nitrogen
atmosphere for 21 h; it was then cooled to rt. The reaction
mixture was partitioned between EtOAc (3 mL) and water (3
mL). The organic phase was washed with brine (3 mL), dried
over magnesium sulfate, filtered, and concentrated. Purification
using automated flash chromatography (EtOAc/hexanes) was
followed by evaporation, giving 8 as a colorless oil (0.026 g,
10%). TLC Rf 0.50 (10% EtOAc/hexanes). LC−MS (ESI) m/z:
257 [M + H]+. 1H NMR (400 MHz, CDCl3) δ 7.22−7.07 (m,
1H), 6.60 (d, J = 7.4 Hz, 1H), 6.18 (d, J = 8.2 Hz, 1H), 4.64−4.47
(br s, 1H), 3.41−3.26 (m, 1H), 1.89−1.96 (m, 2H), 1.72−1.61
(m, 2H), 1.53−1.59 (m, 1H), 1.39−1.23 (m, 2H), 1.23−1.05 (m,
3H). 13C NMR (101 MHz, CDCl3) δ 158.14, 140.32, 139.48,
115.22, 104.14, 50.36, 32.99, 25.66, 24.69.
N2-Cyclohexyl-N6-(3-(pyridin-3-yl)phenyl)pyridine-2,6-dia-
mine (9). A mixture of 8 (0.078 mmol, 1.0 equiv), 3-(pyridin-3-
yl)aniline (0.10 mmol, 1.3 equiv), sodium t-butoxide (0.39
mmol, 5.0 equiv), Pd2(dba)3 (0.005 mmol, 7 mol %), and R-
BINAP (0.012 mmol, 15 mol %) was stirred in toluene (1.0 mL,
0.078 M) at 80 °C under a nitrogen atmosphere for 16 h; it was
then cooled to rt. The reaction mixture was then diluted with
EtOAc (3 mL) and washed with brine (2 × 3 mL). The organic
phase was dried over magnesium sulfate, filtered, and
concentrated. Purification using automated flash chromatog-
raphy (EtOAc/hexanes) was followed by evaporation, giving 9 as
a yellow oil (0.015 g, 56%). TLC Rf 0.70 (80% EtOAc/hexanes).
LC−MS (ESI) m/z: 345 [M + H]+. 1H NMR (500 MHz,
MeOD) δ 8.79 (s, 1H), 8.51 (s, 1H), 8.13−7.96 (m, 2H), 7.60 (d,
J = 8.4 Hz, 1H), 7.58−7.48 (m, 1H), 7.34 (t, J = 8.0 Hz, 1H),
7.26−7.18 (m, 1H), 7.11 (d, J = 7.7 Hz, 1H), 6.02 (d, J = 8.1 Hz,
1H), 5.90 (d, J = 8.0 Hz, 1H), 3.77−3.59 (m, 1H), 2.11−1.93 (m,
2H), 1.75−1.59 (m, 2H), 1.54−1.68 (m, 1H), 1.15−1.22 (m,
5H). 13C NMR (126 MHz, MeOD) δ 157.57, 157.53, 154.95,
154.91, 147.07, 143.20, 138.20, 138.10, 138.00, 137.89, 137.66,
135.29, 129.00, 124.03, 118.50, 117.77, 116.36, 97.90, 97.88,
96.85, 96.83, 49.80, 33.06, 25.60, 24.87.
2-Chloro-N-cyclohexylpyridin-4-amine (11). A mixture of 4-
bromo-2-chloropyridine 10 (4.0 mmol, 1.0 equiv), cyclohexyl-
amine (6.4 mmol, 1.6 equiv), and triethylamine (4.8 mmol, 1.2
equiv) was stirred at 80 °C in NMP (2.0 mL, 2.0 M) under a
nitrogen atmosphere for 16 h. The reaction mixture was cooled
to rt and then partitioned between EtOAc (3 mL) and water (3
mL). The organic phase was washed with brine (3 mL), dried
over magnesium sulfate, filtered, and concentrated. Purification
using automated flash chromatography (EtOAc/hexanes) was
followed by evaporation, giving 11 as an orange solid (0.123 g,
15%). TLC Rf 0.40 (30% EtOAc/hexanes). LC−MS (ESI) m/z:
211 [M + H]+. 1H NMR (400 MHz, CDCl3) δ 7.92 (d, J = 5.8
Hz, 1H), 6.43 (s, 1H), 6.33 (dd, J = 5.8, 2.2 Hz, 1H), 4.26 (d, J =
7.8 Hz, 1H), 3.34−3.22 (m, 1H), 2.13−1.94 (m, 2H), 1.88−1.74
Table 9. Physicochemical Properties of 1, 5e, and 6k
in vitro properties 1 5e 6k
solubility (μM)a pH = 7.4 0.4 ± 0.9 26.4 ± 17.0 56.9 ± 1.9
permeability (10−6 cm/s)a 1880 ± 170 2000 ± 190 1870 ± 60
liver microsome stability at 4 μM t1/2 (h)
a mouse 0.26 ± 0.03 0.30 ± 0.03 0.118 ± 0.003
rat 1.04 ± 0.03 1.1 ± 0.1 0.38 ± 0.01
dog 0.7 ± 0.1 1.2 ± 0.1 0.90 ± 0.02
human 0.8 ± 0.1 2.1 ± 0.1 1.46 ± 0.10
liver microsome stability Clint at 4 μM (mL/min/kg)a mouse 26.5 ± 1.6 179.6 ± 19.4 485.3
rat 44.9 ± 1.4 41.7 ± 2.7 121.98
dog 49.4 ± 3.9 28.2 ± 1.9 37.03
human 26.6 ± 2.2 10.0 ± 0.6 14.22
plasma stability (h)a mouse N.D.b >48 >50
rat N.D.b >48 >50
human N.D.b >48 >50
PBS stability (h)a pH = 7.4 N.D.b >48 N.D.b
pH = 5.0 N.D.b >48 N.D.b
pH = 3.0 N.D.b >48 N.D.b
SGF stability (h)a N.D.b >48 N.D.b
aValues are the mean of a single triplicate experiment. bN.D. means not determined.
Table 10. Pharmacokinetic Parameters in Mice for
Compound 5e (i.p. Dosing)
dose (mg/kg) 3 5 10
Cmax (nM) 376 927 1650
Tmax (h) 0.083 0.083 0.25
T1/2 (h) 0.23 0.54 1
AUC (nM h) 183.3 683.1 953.3
Vz (L/kg) 16.7 18.6 47.3
Cl (L/h/kg) 50.7 23.8 33.1
Figure 4. Summary of SAR.
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(m, 2H), 1.74−1.61 (m, 1H), 1.47−1.32 (m, 2H), 1.32−1.12 (m,
3H). 13C NMR (101 MHz, CDCl3) δ 154.37, 152.16, 149.16,
107.41, 106.04, 51.03, 32.81, 25.54, 24.72.
N4-cyclohexyl-N2-(3-(pyridin-3-yl)phenyl)pyridine-2,4-dia-
mine (13). Amixture of 11 (0.20 mmol, 1.0 equiv), 3-(pyridin-3-
yl)aniline (0.25 mmol, 1.3 equiv), sodium t-butoxide (0.97
mmol, 5.0 equiv), Pd2(dba)3 (0.014 mmol, 7 mol %), and R-
BINAP (0.029 mmol, 0.15 mmol) was stirred in DMF (1.0 mL,
0.20 M) at 140 °C under microwave irradiation at 35 W for 1 h.
The reaction mixture was then cooled to rt, diluted with EtOAc
(5 mL), and washed with brine (5 mL). The organic phase was
dried over magnesium sulfate, filtered, and concentrated.
Purification using automated flash chromatography (MeOH/
CH2Cl2) was followed by evaporation, giving 13 as a brown oil
(0.016 g, 24%). TLC Rf 0.3 (10% MeOH/CH2Cl2). LC−MS
(ESI) m/z: 345 [M + H]+. 1H NMR (400 MHz, CDCl3) δ 8.81
(s, 1H), 8.61−8.56 (m, 1H), 7.86 (dt, J = 7.9, 2.3 Hz, 1H), 7.57−
7.50 (m, 1H), 7.48−7.42 (m, 2H), 7.35−7.38 (m, 1H), 7.27−
7.32 (m, 2H), 6.12 (dd, J = 6.6, 2.1 Hz, 1H), 6.02 (s, 1H), 5.21 (d,
J = 7.6 Hz, 1H), 3.27−3.14 (m, 1H), 1.92−1.97 (m, 2H), 1.76−
1.68 (m, 2H), 1.59−1.61 (m, 1H), 1.16−1.30 (m, 5H). 13CNMR
(101 MHz, CDCl3) δ 155.68, 153.72, 148.79, 148.15, 140.43,
139.34, 139.26, 135.98, 134.40, 130.21, 123.64, 123.14, 121.73,
120.74, 102.29, 87.65, 51.48, 32.59, 25.36, 24.58.
4-Bromo-N-cyclohexylpyridin-2-amine (12). A mixture of 4-
bromo-2-chloropyridine 10 (1.0 mmol, 1.0 equiv), cyclohexyl-
amine (1.6 mmol, 1.6 equiv), and triethylamine (1.2 mmol, 1.2
equiv) was stirred at 80 °C in NMP (1.0 mL, 1.0 M) under a
nitrogen atmosphere for 16 h. The reaction mixture was cooled
to rt and then partitioned between EtOAc (3 mL) and water (3
mL). The organic phase was washed with brine (3 mL), dried
over magnesium sulfate, filtered, and concentrated. Purification
using automated flash chromatography (EtOAc/hexanes) was
followed by evaporation, giving 12 as a colorless oil (0.006 g,
2%). TLC Rf 0.75 (30% EtOAc/hexanes). LC−MS (ESI) m/z:
255 [M + H]+. 1H NMR (400 MHz, CDCl3) δ 7.88 (d, J = 5.5
Hz, 1H), 6.69 (dd, J = 5.5, 1.6 Hz, 1H), 6.55 (d, J = 1.6 Hz, 1H),
4.64 (s, 1H), 3.59−3.42 (m, 1H), 2.08−1.98 (m, 2H), 1.85−1.71
(m, 2H), 1.67 (dt, J = 12.7, 3.9 Hz, 1H), 1.53−1.33 (m, 2H),
1.33−1.14 (m, 3H). 13C NMR (101 MHz, CDCl3) δ 158.62,
148.77, 133.60, 115.61, 109.24, 50.28, 33.17, 25.68, 24.79.
N2-Cyclohexyl-N4-(3-(pyridin-3-yl)phenyl)pyridine-2,4-dia-
mine (14). A mixture of 12 (0.067 mmol, 1.0 equiv), 3-(pyridin-
3-yl)aniline (0.087 mmol, 1.3 equiv), sodium t-butoxide (0.33
mmol, 5.0 equiv), Pd2(dba)3 (0.0047 mmol, 7 mol %), and R-
BINAP (0.010 mmol, 15 mol %) was stirred in toluene (1.0 mL,
0.067 M) at 80 °C under a nitrogen atmosphere. After 16 h, the
reaction mixture was cooled to rt, diluted with EtOAc (3 mL),
and washed with brine (2 × 3 mL). The organic phase was dried
over magnesium sulfate, filtered, and concentrated. Purification
using automated flash chromatography (MeOH/DCM) was
followed by evaporation, giving 14 as a white oil (0.002 g, 9%).
TLC Rf 0.2 (10%MeOH/DCM). LC−MS (ESI)m/z: 345 [M +
H]+. 1H NMR (500 MHz, MeOD) δ 8.84 (s, 1H), 8.58 (s, 1H),
8.14 (d, J = 5.0 Hz, 1H), 7.68−7.46 (m, 5H), 7.39−7.30 (d, J =
5.0 Hz, 1H), 6.44 (dd, J = 7.0, 2.2 Hz, 1H), 6.25 (s, 1H), 3.40−
3.44 (m, 1H), 1.99 (d, J = 15.0 Hz, 2H), 1.77−1.83 (m, 2H), 1.68
(dt, J = 12.8, 3.8 Hz, 1H), 1.37−1.46 (m, 2H), 1.24−1.34 (m,
3H). 13C NMR (126 MHz, MeOD) δ 154.89, 153.53, 147.83,
146.98, 139.59, 138.87, 136.95, 136.53, 135.22, 130.27, 124.16,
123.63, 122.39, 121.05, 102.81, 88.10, 50.49, 32.29, 25.05, 24.37.
2-Chloro-N-cyclohexyl-N-methylpyrimidin-4-amine (15). A
mixture of 2,4-dichloropyrimidine 2 (5.0 mmol, 1.0 equiv), N-
methylaminocyclohexane (5.0 mmol, 1.0 equiv), and triethyl-
amine (5.5 mmol, 1.1 equiv) was stirred in EtOH (7.0 mL, 0.71
M) under a nitrogen atmosphere at reflux temperature for 5 h.
The reaction mixture was then cooled to rt and concentrated.
Purification using automated flash chromatography (EtOAc/
hexanes) was followed by evaporation, giving 15 as a white solid
(0.67 g, 59%). TLC Rf 0.50 (30% EtOAc/hexanes). LC−MS
(ESI) m/z: 228 [M + H]+. 1H NMR (500 MHz, CDCl3) δ 8.00
(d, J = 6.2 Hz, 1H), 6.46−6.17 (m, 1H), 4.72 (br s, 1H), 2.93 (br
s, 3H), 1.97−1.80 (m, 2H), 1.83−1.61 (m, 3H), 1.43−1.52 (m,
4H), 1.23−1.05 (m, 1H). 13C NMR (126 MHz, CDCl3) δ
162.58, 160.52, 156.66, 101.31, 29.82, 25.63, 25.48.
N4-Cyclohexyl-N4-methyl-N2-(3-(pyridin-3-yl)phenyl)-
pyrimidine-2,4-diamine (16). To a mixture of 15 (0.10 mmol,
1.0 equiv) in EtOH (0.50 mL, 0.20 M) under a nitrogen
atmosphere at rt were added 3-(3-pyridyl)aniline (0.11 mmol,
1.1 equiv) and a drop of 1 N HCl. The reaction mixture was
heated to reflux and stirred at that temperature for 3 h; it was then
cooled to rt. Purification using automated flash chromatography
(EtOAc/hexanes) was followed by evaporation, giving 16 as a
colorless oil (0.009 g, 25%). TLC Rf 0.1 (70% EtOAc/hexanes).
LC−MS (ESI) m/z: 360 [M + H]+. 1H NMR (500 MHz,
CDCl3) δ 8.86 (d, J = 2.3 Hz, 1H), 8.58 (dd, J = 4.8, 1.6 Hz, 1H),
7.94−7.84 (m, 2H), 7.61 (d, J = 8.7 Hz, 2H), 7.40 (t, J = 7.9 Hz,
1H), 7.35 (dd, J = 7.9, 4.8 Hz, 1H), 7.19 (d, J = 5.0, 1H), 5.98 (d, J
= 6.3 Hz, 1H), 4.28 (br s, 2H), 2.92 (s, 3H), 1.84−1.72 (m, 2H),
1.70 (d, J = 3.9 Hz, 2H), 1.67−1.56 (m, 1H), 1.45 (q, J = 11.9,
11.1 Hz, 2H), 1.19−1.25 (m, 2H), 1.14−1.00 (m, 1H). 13CNMR
(126 MHz, CDCl3) δ 162.03, 158.45, 154.29, 148.46, 148.44,
140.76, 138.53, 137.01, 134.49, 129.36, 123.47, 120.79, 118.85,
117.89, 95.37, 54.65, 30.01, 29.47, 25.75, 25.55.
N4-Cyclohexyl-N2-methyl-N2-(3-(pyridin-3-yl)phenyl)-
pyrimidine-2,4-diamine (21). To a mixture of 3a (0.10 mmol,
1.0 equiv) in EtOH (0.50 mL, 0.20 M) under a nitrogen
atmosphere at rt were added N-methyl-3-(pyridin-3-yl)aniline
(0.11 mmol, 1.1 equiv) and a drop of 1 N HCl. The reaction
mixture was heated to reflux and stirred at that temperature for 2
h; it was then cooled to rt. Purification using automated flash
chromatography (MeOH/DCM) was followed by evaporation,
giving 21 as a red oil (0.002 g, 6%). TLC Rf 0.2 (10% MeOH/
DCM). LC−MS (ESI)m/z: 360 [M +H]+. 1HNMR (400MHz,
MeOD) δ 10.18 (t, J = 1.7 Hz, 1H), 10.00 (dt, J = 6.3, 1.4 Hz,
1H), 9.05 (dt, J = 8.1, 1.6 Hz, 1H), 8.31 (dd, J = 8.1, 6.3 Hz, 1H),
8.25 (d, J = 6.0 Hz, 1H), 7.38 (t, J = 7.9 Hz, 1H), 7.03−7.08 (m,
1H), 7.02 (t, J = 2.1 Hz, 1H), 6.89−6.79 (m, 1H), 6.73 (d, J = 6.0
Hz, 1H), 4.22−3.97 (m, 1H), 2.89 (s, 3H), 2.11 (d, J = 13.3 Hz,
2H), 1.87 (dt, J = 13.0, 3.7 Hz, 2H), 1.74 (dt, J = 12.9, 3.8 Hz,
1H), 1.58−1.27 (m, 5H). 13C NMR (101 MHz, MeOD) δ
163.12, 149.09, 148.41, 139.93, 137.95, 136.60, 131.55, 127.82,
127.13, 126.40, 125.55, 76.82, 51.05, 39.06, 33.48, 26.68, 26.09.
N4-Cyclohexyl-N2,N4-dimethyl-N2-(3-(pyridin-3-yl)phenyl)-
pyrimidine-2,4-diamine (17). To a mixture of 15 (0.10 mmol,
1.0 equiv) in EtOH (0.50 mL, 0.20 M) under a nitrogen
atmosphere at rt were added N-methyl-3-(pyridin-3-yl)aniline
(0.11 mmol, 1.1 equiv) and a drop of 1 N HCl. The reaction
mixture was heated to reflux and stirred at that temperature for 3
h; it was then cooled to rt. Purification using automated flash
chromatography (MeOH/DCM) was followed by evaporation,
giving 17 as an orange oil (0.010 g, 27%). TLC Rf 0.4 (10%
MeOH/DCM). LC−MS (ESI) m/z: 374 [M + H]+. 1H NMR
(500 MHz, MeOD) δ 10.19 (s, 1H), 10.01 (d, J = 7.4 Hz, 1H),
9.06 (d, J = 8.1 Hz, 1H), 8.42 (t, J = 7.2 Hz, 1H), 8.33 (t, J = 7.2
Hz, 1H), 7.38 (t, J = 7.9 Hz, 1H), 7.08 (d, J = 7.5Hz, 1H), 7.03 (s,
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J = 2.0 Hz, 1H), 6.98−6.88 (m, 1H), 6.84 (d, J = 5.0 Hz, 1H),
3.95 (s, 1H), 3.09−3.26 (m, 3H), 2.89 (s, 3H), 2.02−1.89 (m,
2H), 1.83−1.86 (m, 2H), 1.67−1.77 (m, 3H), 1.56 (qt, J = 13.2,
3.6 Hz, 2H), 1.38−1.23 (m, 1H). 13C NMR (126 MHz, MeOD)
δ 162.46, 156.01, 155.64, 151.30, 146.51, 141.80, 138.18, 137.88,
134.24, 130.11, 127.39, 114.72, 114.23, 109.54, 105.17, 55.20,
29.23, 29.05, 25.53, 25.14.
2-Chloro-4-(cyclohexyloxy)pyrimidine (18). To a solution of
cyclohexanol (6.0 mmol, 1.2 equiv) inDMF (10mL, 0.60M) at 0
°Cwas addedNaH as a 60% suspension inmineral oil (7.5 mmol,
1.5 equiv). After stirring for 20 min, 2,4-dichloropyrimidine 2
(5.0 mmol, 1.0 equiv) was added at 0 °C to one portion. The
reaction mixture was then stirred under a nitrogen atmosphere
while warming to rt over 16 h. Brine (20 mL) was added to the
reaction mixture; then, the mixture was extracted into EtOAc (2
× 20 mL). The organic phase was dried over magnesium sulfate,
filtered, and concentrated. Purification using automated flash
chromatography (EtOAc/hexanes) was followed by evaporation,
giving 18 as a white solid (0.031 g, 3%). TLC Rf 0.35 (10%
EtOAc/hexanes). LC−MS (ESI) m/z: 213 [M + H]+. 1H NMR
(400MHz, CDCl3) δ 8.18 (d, J = 5.7 Hz, 1H), 6.53 (d, J = 5.7 Hz,
1H), 5.17−4.97 (m, 1H), 2.00−1.84 (m, 2H), 1.78−1.63 (m,
2H), 1.56−1.49 (m, 2H), 1.35−1.48 (m, 3H), 1.19−1.34 (m,
1H). 13C NMR (101 MHz, CDCl3) δ 170.02, 160.21, 158.63,
107.61, 75.52, 31.32, 25.36, 23.60.
4-(Cyclohexyloxy)-N-(3-(pyridin-3-yl)phenyl)pyrimidin-2-
amine (19). To a mixture of 18 (0.10 mmol, 1.0 equiv) in EtOH
(0.50 mL, 0.20 M) under a nitrogen atmosphere at rt were added
3-(pyridin-3-yl)aniline (0.11 mmol, 1.1 equiv) and a drop of 1 N
HCl. The reaction mixture was heated to reflux and stirred at that
temperature for 3 h; it was then cooled to rt. Purification using
automated flash chromatography (MeOH/DCM) was followed
by evaporation, giving 19 as an orange oil (0.003 g, 9%). TLC Rf
0.3 (10%MeOH/DCM). LC−MS (ESI)m/z: 347 [M +H]+. 1H
NMR (500 MHz, MeOD) δ 10.17 (d, J = 1.8 Hz, 1H), 10.02 (dt,
J = 6.3, 1.8 Hz, 1H), 9.09 (dt, J = 8.1, 2.2 Hz, 1H), 8.79 (t, J = 6.1
Hz, 1H), 8.37 (dd, J = 8.0, 6.3 Hz, 1H), 7.36 (t, J = 7.8 Hz, 1H),
7.27−7.07 (m, 3H), 6.94 (dd, J = 8.0, 2.3 Hz, 1H), 5.40−5.45 (m,
1H), 2.13−2.18 (m, 2H), 1.96−1.83 (m, 2H), 1.70−1.78 (m,
3H), 1.65−1.53 (m, 2H), 1.44−1.49 (m, 1H). 13C NMR (126
MHz, MeOD) δ 171.00, 159.02, 154.69, 149.51, 147.06, 141.78,
138.57, 138.14, 134.01, 130.30, 127.67, 116.71, 115.78, 112.77,
111.06, 77.04, 30.86, 25.03, 23.13.
N-Cyclohexyl-2-(3-(pyridin-3-yl)phenoxy)pyrimidin-4-
amine (22). To a mixture of 3a (0.10 mmol, 1.0 equiv) in EtOH
(0.50 mL, 0.20 M) under a nitrogen atmosphere at rt were added
3-(pyridin-3-yl)phenol (0.11 mmol, 1.1 equiv) and a drop of 1 N
HCl. The reaction mixture was heated to reflux and stirred at that
temperature for 16 h; it was then cooled to rt. Purification using
automated flash chromatography (MeOH/DCM) was followed
by evaporation, giving 22 as a yellow oil (0.028 g, 81%). TLC Rf
0.1 (10%MeOH/DCM). LC−MS (ESI)m/z: 347 [M +H]+. 1H
NMR (500MHz, MeOD) δ 10.19 (d, J = 9.9 Hz, 1H), 10.01 (d, J
= 10.0Hz, 1H), 9.05 (d, J = 9.1Hz, 1H), 8.29 (dt, J = 41.0, 6.6 Hz,
2H), 7.46 (t, J = 9.8 Hz, 1H), 7.40−7.23 (m, 2H), 7.04 (d, J = 9.0
Hz, 1H), 6.82−6.65 (m, 1H), 4.10 (m, 1H), 2.11 (m, 2H), 2.00−
1.81 (m, 2H), 1.73 (m, 1H), 1.64−1.26 (m, 5H). 13C NMR (126
MHz, MeOD) δ 162.96, 158.68, 154.25, 146.51, 140.85, 138.31,
137.88, 134.78, 130.67, 127.49, 117.99, 117.09, 113.84, 107.95,
49.88, 31.93, 25.33, 24.58.
4-(Cyclohexyloxy)-2-(3-(pyridin-3-yl)phenoxy)pyrimidine
(20). To a mixture of 18 (0.10 mmol, 1.0 equiv) in EtOH (0.50
mL, 0.20 M) under a nitrogen atmosphere at rt were added 3-
(pyridin-3-yl)phenol (0.11 mmol, 1.1 equiv) and a drop of 1 N
HCl. The reaction mixture was heated to reflux and stirred at that
temperature for 16 h; it was then cooled to rt. Purification using
automated flash chromatography (MeOH/DCM) was followed
by evaporation, giving 20 as a yellow solid (0.018 g, 52%). TLC
Rf 0.3 (10%MeOH/DCM). LC−MS (ESI)m/z: 348 [M + H]+.
1H NMR (400 MHz, MeOD) δ 10.19 (t, J = 1.7 Hz, 1H), 10.05
(dt, J = 6.4, 1.4 Hz, 1H), 9.13 (ddd, J = 8.1, 2.0, 1.2 Hz, 1H), 8.79
(d, J = 5.8 Hz, 1H), 8.39 (dd, J = 8.1, 6.4 Hz, 1H), 7.48 (t, J = 7.9
Hz, 1H), 7.36 (ddd, J = 7.7, 1.9, 1.0 Hz, 1H), 7.31 (t, J = 2.1 Hz,
1H), 7.21 (d, J = 5.8 Hz, 1H), 7.06 (ddd, J = 8.2, 2.4, 0.9 Hz, 1H),
5.42−5.45 (m, 1H), 2.25−2.07 (m, 2H), 1.86−1.92 (m, 2H),
1.67−1.78 (m, 3H), 1.64−1.52 (m, 2H), 1.44−1.49 (m, 1H). 13C
NMR (101 MHz, MeOD) δ 172.42, 160.45, 160.12, 148.65,
142.60, 140.21, 139.72, 136.02, 132.14, 129.17, 119.49, 118.62,
115.32, 112.51, 78.48, 32.28, 26.45, 24.56.
N4-Cyclohexyl-N2-phenylpyrimidine-2,4-diamine (4a). To a
mixture of 3a (0.10 mmol, 1.0 equiv) in EtOH (0.50mL, 0.20M)
under a nitrogen atmosphere at rt were added aniline (0.20
mmol, 2.0 equiv) and a drop of 1 N HCl. The reaction mixture
was heated to reflux and stirred at that temperature for 1.5 h; it
was then cooled to rt. Purification using automated flash
chromatography (MeOH/DCM) was followed by evaporation,
giving 4a as a white solid (0.018 g, 67%). TLC Rf 0.7 (10%
MeOH/DCM). LC−MS (ESI) m/z: 269 [M + H]+. 1H NMR
(500 MHz, CDCl3) δ 7.90−7.72 (m, 1H), 7.53 (d, J = 7.9 Hz,
2H), 7.25−7.20 (m, 2H), 7.19 (br s, 1H), 6.92 (t, J = 7.4 Hz, 1H),
5.75 (d, J = 5.9 Hz, 1H), 4.71 (br s, 1H), 3.60 (br s, 1H), 2.05−
1.92 (m, 2H), 1.69−1.75 (m, 2H), 1.58−1.62 (m, 1H), 1.29−
1.38 (m, 2H), 1.21−1.08 (m, 3H). 13C NMR (126MHz, CDCl3)
δ 162.03, 159.44, 139.97, 128.73, 121.97, 119.23, 50.07, 33.09,
25.62, 24.93.
N2-([1,1′-Biphenyl]-2-yl)-N4-cyclohexylpyrimidine-2,4-dia-
mine (4b). To a mixture of 3a (0.10 mmol, 1.0 equiv) in EtOH
(0.50 mL, 0.20 M) under a nitrogen atmosphere at rt were added
2-aminobiphenyl (0.20 mmol, 2.0 equiv) and a drop of 1 N HCl.
The reaction mixture was heated to reflux and stirred at that
temperature for 1.5 h; it was then cooled to rt. Purification using
automated flash chromatography (MeOH/DCM) was followed
by evaporation, giving 4b as a colorless oil (0.023 g, 67%). TLC
Rf 0.45 (5%MeOH/DCM). LC−MS (ESI)m/z: 345 [M + H]+.
1H NMR (400 MHz, CDCl3) δ 8.35 (d, J = 8.3 Hz, 1H), 7.78 (s,
1H), 7.51−7.39 (m, 4H), 7.32−7.37 (m, 2H), 7.29−7.20 (m,
2H), 7.09 (td, J = 7.5, 1.2 Hz, 1H), 5.81 (d, J = 6.0 Hz, 1H), 4.97
(br s, 1H), 3.60 (br s, 1H), 1.98−2.04 (m, 2H), 1.74−1.80 (m,
2H), 1.63−1.68 (m, 1H), 1.44−1.29 (m, 2H), 1.15−1.27 (m,
3H). 13C NMR (101 MHz, CDCl3) δ 161.95, 138.81, 136.42,
132.54, 130.24, 129.40, 128.92, 127.85, 127.59, 122.62, 121.18,
50.14, 33.00, 25.56, 24.87.
N4-Cyclohexyl-N2-(3-cyclopropylphenyl)pyrimidine-2,4-di-
amine (4c). To a mixture of 3a (0.10 mmol, 1.0 equiv) in EtOH
(0.50 mL, 0.20 M) under a nitrogen atmosphere at rt were added
3-cyclopropylaniline (0.11 mmol, 1.1 equiv) and a drop of 1 N
HCl. The reaction mixture was heated to reflux and stirred at that
temperature for 4 h; it was then cooled to rt. Purification using
automated flash chromatography (MeOH/DCM) was followed
by evaporation, giving 4c as a white oil (0.009 g, 29%). TLC Rf
0.6 (10%MeOH/DCM). LC−MS (ESI)m/z: 309 [M +H]+. 1H
NMR (500 MHz, CDCl3) δ 7.76 (d, J = 6.2 Hz, 1H), 7.35−7.37
(m, 2H), 7.20 (s, 1H), 7.10 (t, J = 7.9Hz, 1H), 6.63 (d, J = 5.0Hz,
1H), 5.76 (d, J = 6.0 Hz, 1H), 4.88 (d, J = 8.0 Hz, 1H), 3.77−3.46
(m, 1H), 1.95−2.00 (m, 2H), 1.80−1.83 (m, 1H), 1.70 (dt, J =
13.6, 3.9 Hz, 2H), 1.59 (dt, J = 13.0, 3.8 Hz, 1H), 1.40−1.24 (m,
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2H), 1.24−1.09 (m, 3H), 0.91−0.79 (m, 2H), 0.70−0.56 (m,
2H). 13C NMR (126 MHz, CDCl3) δ 162.02, 158.97, 153.51,
144.68, 139.65, 128.60, 119.35, 117.17, 116.73, 96.62, 49.98,
33.06, 25.58, 24.88, 15.58, 9.15.
N4-Cyclohexyl-N2-(3-fluorophenyl)pyrimidine-2,4-diamine
(4d). To a mixture of 3a (0.10 mmol, 1.0 equiv) in EtOH (0.50
mL, 0.20 M) at rt were added 3-fluoroaniline (0.20 mmol, 2.0
equiv) and a drop of 1 N HCl. The reaction mixture was heated
to reflux and stirred at that temperature for 1.5 h; it was then
cooled to rt. Purification using automated flash chromatography
(MeOH/DCM) was followed by evaporation, giving 4d as a
white solid (0.018 g, 63%). TLC Rf 0.7 (10% MeOH/DCM).
LC−MS (ESI) m/z: 287 [M + H]+. 1H NMR (500 MHz,
CDCl3) δ 7.90 (d, J = 6.0 Hz, 1H), 7.78 (d, J = 12.0 Hz, 1H), 7.30
(s, 1H), 7.19 (dd, J = 8.2, 6.7 Hz, 1H), 7.07 (dd, J = 8.1, 2.1 Hz,
1H), 6.66 (td, J = 8.3, 2.5 Hz, 1H), 5.85 (d, J = 5.8 Hz, 1H), 4.76
(br s, 1H), 3.72 (br s, 1H), 2.16−2.00 (m, 2H), 1.77−1.81 (m,
2H), 1.66−1.70 (m, 1H), 1.50−1.35 (m, 2H), 1.19−1.27 (m,
3H). 13C NMR (126 MHz, CDCl3) δ 164.17, 162.25, 161.98,
159.34, 141.88, 141.79, 129.65, 129.57, 114.11, 114.08, 108.21,
108.04, 106.15, 105.93, 50.12, 33.11, 25.62, 24.90.
N4-Cyclohexyl-N2-(pyridin-3-yl)pyrimidine-2,4-diamine
(4e). To a mixture of 3a (0.10 mmol, 1.0 equiv) in EtOH (0.50
mL, 0.20 M) under a nitrogen atmosphere at rt were added 3-
aminopyridine (0.20 mmol, 2.0 equiv) and a drop of 1 N HCl.
The reaction mixture was heated to reflux and stirred at that
temperature for 1.5 h; it was then cooled to rt. Purification using
automated flash chromatography (MeOH/DCM) was followed
by evaporation, giving 4e as a yellow oil (0.023 g, 85%). TLC Rf
0.4 (10%MeOH/DCM). LC−MS (ESI)m/z: 270 [M +H]+. 1H
NMR (400MHz,MeOD) δ 9.29 (d, J = 2.3 Hz, 1H), 9.17 (dt, J =
5.1, 1.7 Hz, 1H), 8.17 (d, J = 6.0 Hz, 1H), 7.95−7.76 (m, 2H),
6.67 (d, J = 6.0 Hz, 1H), 4.22−3.98 (m, 1H), 2.11−1.96 (m, 2H),
1.82−1.87 (m, 2H), 1.78−1.66 (m, 1H), 1.48−1.55 (m, 2H),
1.44−1.19 (m, 3H). 13C NMR (126 MHz, CDCl3) δ 166.85,
159.11, 158.07, 152.94, 134.51, 131.01, 128.10, 111.57, 53.28,
35.98, 29.22, 28.41.
Methyl 3-((4-(cyclohexylamino)pyrimidin-2-yl)amino)-
benzoate (4f). To a mixture of 3a (0.10 mmol, 1.0 equiv) in
MeOH (0.50 mL, 0.20 M) under a nitrogen atmosphere at rt
were added 3-aminobenzoic acid methyl ester (0.11 mmol, 1.1
equiv) and a drop of 1 N HCl. The reaction mixture was heated
to reflux and stirred at that temperature for 2 h; it was then cooled
to rt. Purification using automated flash chromatography
(MeOH/DCM) was followed by evaporation, giving 4f as a
colorless oil (0.018 g, 55%). TLC Rf 0.6 (10% MeOH/DCM).
LC−MS (ESI) m/z: 327 [M + H]+. 1H NMR (500 MHz,
CDCl3) δ 8.21 (s, 1H), 7.98−7.82 (m, 2H), 7.66 (d, J = 5.0 Hz,
1H), 7.61 (s, 1H), 7.35 (t, J = 7.9 Hz, 1H), 5.86 (d, J = 5.9 Hz,
1H), 4.88 (br s, 1H), 3.91 (s, 3H), 3.08 (br s, 1H), 2.11−1.96 (m,
2H), 1.76 (dt, J = 13.7, 3.9 Hz, 2H), 1.70−1.60 (m, 1H), 1.47−
1.31 (m, 2H), 1.19−1.25 (m, 3H). 13CNMR (126MHz, CDCl3)
δ 167.13, 162.02, 159.21, 154.87, 140.20, 130.65, 128.74, 123.60,
123.02, 120.18, 52.12, 49.94, 33.05, 25.60, 24.80.
N2-([1,1′-Biphenyl]-3-yl)-N4-cyclohexylpyrimidine-2,4-dia-
mine (4g). To a mixture of 3a (0.10 mmol, 1.0 equiv) in EtOH
(0.50 mL, 0.20 M) under a nitrogen atmosphere at rt were added
3-aminobiphenyl (0.20 mmol, 2.0 equiv) and a drop of 1 N HCl.
The reaction mixture was heated to reflux and stirred at that
temperature for 1.5 h; it was then cooled to rt. Purification using
automated flash chromatography (MeOH/DCM) was followed
by evaporation, giving 4g as a white solid (0.018 g, 52%). TLC Rf
0.5 (5% MeOH/DCM). LC−MS (ESI) m/z: 345 [M + H]+. 1H
NMR (400 MHz, CDCl3) δ 7.84 (s, 2H), 7.59−7.62 (m, 3H),
7.43 (dd, J = 8.2, 6.9 Hz, 2H), 7.37−7.31 (m, 2H), 7.23 (dt, J =
7.7, 1.4Hz, 1H), 5.86 (d, J = 6.0Hz, 1H), 4.97 (d, J = 8.0Hz, 1H),
3.71 (s, 1H), 2.10−1.92 (m, 2H), 1.77−1.64 (m, 2H), 1.59 (d, J =
11.9 Hz, 1H), 1.36−1.09 (m, 5H). 13C NMR (101MHz, CDCl3)
δ 162.02, 142.00, 141.39, 140.04, 129.07, 128.67, 127.28, 121.29,
118.42, 50.06, 33.02, 25.53, 24.73.
N4-Cyclohexyl-N2-(3-(pyridin-2-yl)phenyl)pyrimidine-2,4-
diamine (4h). To a mixture of 3a (0.10 mmol, 1.0 equiv) in
EtOH (0.50 mL, 0.20M) under a nitrogen atmosphere at rt were
added 3-(pyridin-2-yl)aniline (0.11 mmol, 1.1 equiv) and a drop
of 1 NHCl. The reaction mixture was heated to reflux and stirred
at that temperature for 3 h; it was then cooled to rt. Purification
using automated flash chromatography (MeOH/DCM) was
followed by evaporation, giving 4h as a white film (0.007 g, 20%).
TLC Rf 0.5 (10%MeOH/DCM). LC−MS (ESI)m/z: 346 [M +
H]+. 1HNMR (500MHz, MeOD) δ 8.74−8.58 (m, 1H), 8.27 (s,
1H), 7.95 (td, J = 7.7, 1.8 Hz, 1H), 7.89−7.94 (m, 1H), 7.73 (d, J
= 7.4 Hz, 1H), 7.70−7.63 (m, 1H), 7.60−7.55 (m, 1H), 7.52 (t, J
= 7.8 Hz, 1H), 7.41−7.43 (m, 1H), 6.14 (d, J = 7.0 Hz, 1H), 3.90
(s, 1H), 2.06−1.89 (m, 2H), 1.74−1.60 (m, 2H), 1.60−1.49 (m,
1H), 1.30−1.21 (m, 2H), 1.21−1.05 (m, 3H). 13C NMR (126
MHz, MeOD) δ 161.97, 157.24, 154.20, 149.00, 143.49, 140.02,
138.14, 137.66, 122.94, 122.63, 122.01, 121.48, 120.39, 98.62,
50.18, 31.86, 25.07, 24.52.
N4-Cyclohexyl-N2-(3′-methoxy-[1,1′-biphenyl]-3-yl)-
pyrimidine-2,4-diamine (4i).To amixture of 3a (0.10mmol, 1.0
equiv) in EtOH (0.50 mL, 0.20 M) under a nitrogen atmosphere
at rt were added (3′-methoxybiphenyl-3-yl)amine HCl (0.11
mmol, 1.1 equiv) and a drop of 1 N HCl. The reaction mixture
was heated to reflux and stirred at that temperature for 3 h; it was
then cooled to rt. Purification using automated flash chromatog-
raphy (EtOAc/hexanes) was followed by evaporation, giving 4i
as a colorless oil (0.007 g, 19%). TLC Rf 0.2 (50% EtOAc/
hexanes + 1% MeOH). LC−MS (ESI) m/z: 375 [M + H]+. 1H
NMR (500 MHz, CDCl3) δ 7.98−7.89 (m, 1H), 7.85 (s, 1H),
7.63−7.65 (m, 1H), 7.35−7.37 (m, 2H), 7.21−7.24 (m, 2H),
7.18 (s, 1H), 7.15−7.16 (m, 1H), 6.90−6.93 (m, 1H), 5.85 (d, J =
5.9 Hz, 1H), 4.71 (s, 1H), 3.89 (s, 3H), 3.84−3.57 (m, 1H),
2.03−2.07 (m, 2H), 1.81−1.68 (m, 2H), 1.68−1.56 (m, 1H),
1.39−1.27 (m, 2H), 1.17−1.25 (m, 3H). 13C NMR (126 MHz,
CDCl3) δ 162.06, 159.85, 159.82, 155.82, 143.05, 141.85, 140.49,
129.64, 129.03, 120.89, 119.83, 118.28, 118.07, 112.97, 112.67,
95.81, 55.30, 49.85, 33.12, 25.61, 24.74.
Methyl 3′-((4-(cyclohexylamino)pyrimidin-2-yl)amino)-
[1,1′-biphenyl]-3-carboxylate (4j). To a mixture of 3a (0.10
mmol, 1.0 equiv) in EtOH (0.50 mL, 0.20 M) under a nitrogen
atmosphere at rt were added 3′-aminobiphenyl-3-carboxylic acid
methyl ester HCl (0.11 mmol, 1.1 equiv) and a drop of 1 N HCl.
The reaction mixture was heated to reflux and stirred at that
temperature for 3 h; it was then cooled to rt. Purification using
automated flash chromatography (MeOH/DCM) was followed
by evaporation, giving 4j as a white solid (0.012 g, 30%). TLC Rf
0.2 (50% EtOAc/hexanes + 1% MeOH). LC−MS (ESI) m/z:
375 [M +H]+. 1HNMR (500MHz, CDCl3) δ 8.31 (t, J = 1.8 Hz,
1H), 8.04 (dt, J = 7.8, 1.4 Hz, 1H), 7.97−7.87 (m, 2H), 7.82
(ddd, J = 7.8, 1.9, 1.2 Hz, 1H), 7.64 (ddd, J = 8.1, 2.3, 1.0 Hz, 1H),
7.53 (t, J = 7.7 Hz, 1H), 7.40 (t, J = 7.9 Hz, 1H), 7.26 (ddd, J =
7.7, 1.8, 1.0 Hz, 1H), 7.20 (s, 1H), 5.86 (d, J = 5.9 Hz, 1H), 4.74
(br s, 1H), 3.97 (br s, 3H), 3.86−3.56 (m, 1H), 2.11−1.99 (m,
2H), 1.78−1.67 (m, 2H), 1.61 (d, J = 11.2 Hz, 1H), 1.36−1.13
(m, 5H). 13CNMR (126MHz, CDCl3) δ 167.09, 162.04, 159.62,
155.39, 141.74, 140.83, 140.59, 131.68, 130.59, 129.22, 128.77,
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128.42, 128.31, 120.85, 118.56, 117.98, 77.27, 52.19, 49.89,
33.08, 25.56, 24.75.
N4-Cyclohexyl-N2-(3-(oxazol-2-yl)phenyl)pyrimidine-2,4-
diamine (4k). To a mixture of 3a (0.10 mmol, 1.0 equiv) in
EtOH (0.50 mL, 0.20M) under a nitrogen atmosphere at rt were
added 3-(1,3-oxaxol-2-yl)aniline (0.11 mmol, 1.1 equiv) and a
drop of 1 N HCl. The reaction mixture was heated to reflux and
stirred at that temperature for 2 h; it was then cooled to rt.
Purification using automated flash chromatography (MeOH/
DCM) was followed by evaporation, giving 4k as a white solid
(0.022 g, 66%). TLC Rf 0.6 (10%MeOH/DCM). LC−MS (ESI)
m/z: 336 [M +H]+. 1HNMR (500MHz, CDCl3) δ 8.40 (s, 1H),
7.97−7.83 (m, 1H), 7.76−7.65 (m, 3H), 7.41 (s, 1H), 7.28 (s,
1H), 7.25 (s, 1H), 5.89 (d, J = 6.0 Hz, 1H), 5.04 (br s, 1H), 3.74
(br s, 1H), 2.13−2.01 (m, 2H), 1.76−1.80 (m, 2H), 1.65−1.69
(m, 1H), 1.47−1.34 (m, 2H), 1.21−1.29 (m, 3H). 13C NMR
(126 MHz, CDCl3) δ 162.08, 162.02, 158.70, 140.30, 138.48,
129.23, 128.37, 127.92, 121.20, 120.13, 117.01, 50.03, 33.08,
25.57, 24.81.
N2-(3-(1H-Pyrazol-3-yl)phenyl)-N4-cyclohexylpyrimidine-
2,4-diamine (4l). To a mixture of 3a (0.10 mmol, 1.0 equiv) in
EtOH (0.50 mL, 0.20M) under a nitrogen atmosphere at rt were
added 3-(1H-pyrazol-3-yl)aniline (0.11 mmol, 1.1 equiv) and a
drop of 1 N HCl. The reaction mixture was heated to reflux and
stirred at that temperature for 2 h; it was then cooled to rt.
Purification using automated flash chromatography (MeOH/
DCM) was followed by evaporation, giving 4l as a colorless oil
(0.020 g, 60%). TLC Rf 0.6 (10%MeOH/DCM). LC−MS (ESI)
m/z: 335 [M +H]+. 1HNMR (500MHz,MeOD) δ 8.08 (s, 1H),
7.69 (d, J = 16.6 Hz, 2H), 7.56 (d, J = 8.0 Hz, 1H), 7.43 (d, J = 8.0
Hz, 1H), 7.36 (td, J = 7.8, 1.8 Hz, 1H), 6.67 (d, J = 2.5 Hz, 1H),
5.99 (dd, J = 6.4, 1.8 Hz, 1H), 3.92 (s, 1H), 2.00−2.02 (m, 2H),
1.72−1.75 (m, 2H), 1.61−1.63 (m, 1H), 1.19−1.31 (m, 5H). 13C
NMR (126 MHz, MeOD) δ 162.23, 158.06, 150.32, 140.11,
128.66, 119.78, 119.48, 117.56, 102.17, 97.88, 49.48, 32.36,
25.35, 24.70.
N2-(3-(1H-Imidazol-1-yl)phenyl)-N4-cyclohexylpyrimidine-
2,4-diamine (4m). To a mixture of 3a (0.10 mmol, 1.0 equiv) in
EtOH (0.50 mL, 0.20M) under a nitrogen atmosphere at rt were
added 3-(1H-imidazol-1-yl)aniline (0.11 mmol, 1.1 equiv) and a
drop of 1 N HCl. The reaction mixture was heated to reflux and
stirred at that temperature for 20 h; it was then cooled to rt.
Purification using automated reversed-phase flash chromatog-
raphy (water/MeOH) was followed by evaporation, giving 4m as
a colorless oil (0.010 g, 30%). LC−MS (ESI)m/z: 335 [M+H]+.
1H NMR (400 MHz, MeOD) δ 8.50 (br s, 1H), 8.46 (d, J = 2.2
Hz, 1H), 8.16−8.01 (m, 2H), 7.35 (t, J = 8.0 Hz, 1H), 7.06−6.95
(m, 2H), 6.91 (ddd, J = 8.2, 2.1, 0.9 Hz, 1H), 6.56 (d, J = 6.1 Hz,
1H), 4.13−4.14 (m, 1H), 2.11−1.97 (m, 2H), 1.81−1.86 (m,
2H), 1.70−1.74 (m, 1H), 1.57−1.44 (m, 2H), 1.36−1.39 (m,
3H). 13C NMR (101 MHz, MeOD) δ 164.23, 155.53, 153.70,
151.78, 137.14, 131.98, 123.60, 120.79, 117.54, 111.20, 108.63,
107.95, 50.50, 33.57, 26.75, 25.94.
N4-Cyclohexyl-N2-(3-(pyrazin-2-yl)phenyl)pyrimidine-2,4-
diamine (4n). To a mixture of 3a (0.10 mmol, 1.0 equiv) in
EtOH (0.50 mL, 0.20M) under a nitrogen atmosphere at rt were
added 3-(pyrazin-2-yl)aniline (0.11 mmol, 1.1 equiv) and a drop
of 1 NHCl. The reaction mixture was heated to reflux and stirred
at that temperature for 5 h; it was then cooled to rt. Purification
using automated flash chromatography (MeOH/EtOAc) was
followed by evaporation, giving 4n as a colorless oil (0.007 g,
20%). TLC Rf 0.7 (10% MeOH/EtOAc). LC−MS (ESI) m/z:
347 [M + H]+. 1H NMR (400 MHz, MeOD) δ 9.13 (d, J = 1.6
Hz, 1H), 8.75−8.67 (m, 1H), 8.57 (d, J = 2.5 Hz, 1H), 8.43 (s,
1H), 7.72 (t, J = 8.7 Hz, 3H), 7.49 (t, J = 7.9 Hz, 1H), 6.02 (d, J =
6.3 Hz, 1H), 3.91 (s, 1H), 1.99−2.03 (m, 2H), 1.70−1.72 (m,
2H), 1.60 (s, 1H), 1.37−1.13 (m, 5H). 13C NMR (101 MHz,
MeOD) δ 163.62, 158.67, 154.55, 145.64, 144.08, 143.40,
141.62, 138.07, 130.47, 123.02, 122.50, 120.22, 101.40, 51.02,
33.61, 26.67, 26.06.
N4-Cyclohexyl-N2-(3-morpholinophenyl)pyrimidine-2,4-di-
amine (4o). To a mixture of 3a (0.10 mmol, 1.0 equiv) in EtOH
(0.50 mL, 0.20 M) under a nitrogen atmosphere at rt were added
3-morpholin-4-ylaniline (0.11 mmol, 1.1 equiv) and a drop of 1
N HCl. The reaction mixture was heated to reflux and stirred at
that temperature for 3 h; it was then cooled to rt. Purification
using automated flash chromatography (MeOH/DCM) was
followed by evaporation, giving 4o as a white oil (0.018 g, 51%).
TLC Rf 0.4 (5% MeOH/DCM). LC−MS (ESI) m/z: 354 [M +
H]+. 1H NMR (400MHz, CDCl3) δ 7.62 (s, 1H), 7.21 (d, J = 6.6
Hz, 3H), 7.11−7.02 (m, 1H), 6.64 (dd, J = 5.7, 3.4 Hz, 1H), 5.98
(d, J = 6.7 Hz, 1H), 3.91−3.70 (m, 5H), 3.22−3.10 (m, 4H),
2.10−1.93 (m, 2H), 1.76−1.82 (m, 2H), 1.64−1.69 (m, 1H),
1.46−1.12 (m, 5H). 13C NMR (101 MHz, CDCl3) δ 161.86,
151.96, 138.95, 129.33, 112.24, 111.16, 107.93, 66.89, 50.64,
49.30, 32.63, 25.36, 24.77.
N4-Cyclohexyl-N2-(1-phenylpiperidin-3-yl)pyrimidine-2,4-
diamine (4p). To a mixture of 3a (0.10 mmol, 1.0 equiv) in
EtOH (0.50 mL, 0.20M) under a nitrogen atmosphere at rt were
added 1-phenylpiperidin-3-amine (0.11 mmol, 1.1 equiv) and a
drop of 1 N HCl. The reaction mixture was heated to reflux and
stirred at that temperature for 22 h; it was then cooled to rt.
Purification using automated flash chromatography (MeOH/
EtOAc) was followed by evaporation, giving 4p as a colorless oil
(0.002 g, 6%). TLC Rf 0.3 (10%MeOH/EtOAc). LC−MS (ESI)
m/z: 352 [M+H]+. 1HNMR (500MHz,MeOD) δ 7.58 (s, 1H),
7.23 (t, J = 10.0 Hz, 2H), 7.00 (d, J = 8.1 Hz, 2H), 6.83 (t, J = 7.3
Hz, 1H), 5.84 (d, J = 6.5 Hz, 1H), 4.17−4.03 (m, 1H), 3.87 (s,
1H), 3.70 (d, J = 11.6 Hz, 1H), 3.44−3.36 (m, 1H), 2.93 (t, J =
15.0 Hz, 1H), 2.82−2.73 (m, 1H), 1.98 (d, J = 8.1Hz, 3H), 1.96−
1.86 (m, 1H), 1.79−1.71 (m, 2H), 1.58−1.65 (m, 2H), 1.31−
1.40 (m, 2H), 1.20−1.29 (m, 3H). 13C NMR (126 MHz,
MeOD) δ 162.32, 151.98, 128.59, 119.61, 116.99, 55.38, 50.15,
49.16, 32.45, 32.40, 29.61, 25.36, 24.67, 23.24.
N4-Cyclohexyl-N2-(3-(pyridin-3-yl)cyclohexyl)pyrimidine-
2,4-diamine (4q). To a mixture of 3a (0.080 mmol, 1.0 equiv) in
EtOH (0.50 mL, 0.16M) under a nitrogen atmosphere at rt were
added 3-(pyridin-3-yl)cyclohexan-1-amine (0.080 mmol, 1.0
equiv) and a drop of 1 N HCl. The reaction mixture was heated
to reflux and stirred at that temperature for 6 h; it was then cooled
to rt. Purification using automated flash chromatography
(MeOH/DCM) was followed by evaporation, giving 4q as a
yellow oil (0.002 g, 7%). TLC Rf 0.2 (10% MeOH/DCM). LC−
MS (ESI) m/z: 353 [M + H]+. 1H NMR (500 MHz, MeOD) δ
9.91 (d, J = 7.0 Hz, 2H), 8.79 (d, J = 8.0 Hz, 1H), 8.22 (q, J = 5.0
Hz, 2H), 6.70 (d, J = 6.0 Hz, 1H), 4.18−4.04 (m, 1H), 3.78 (td, J
= 10.8, 5.4 Hz, 1H), 3.11 (t, J = 12.3Hz, 1H), 2.28 (d, J = 11.3Hz,
1H), 2.13−2.05 (m, 3H), 2.05−1.96 (m, 2H), 1.84−1.89 (m,
2H), 1.74 (dt, J = 12.8, 4.1 Hz, 1H), 1.48−1.63 (m, 4H), 1.44−
1.28 (m, 4H). 13C NMR (126 MHz, MeOD) δ 162.95, 155.05,
154.22, 147.78, 146.83, 138.49, 138.24, 127.22, 107.83, 69.34,
49.71, 41.40, 39.97, 34.25, 32.11, 31.96, 25.32, 24.56, 23.72.
N4-Cyclohexyl-N2-(4-fluorophenyl)pyrimidine-2,4-diamine
(4r). To a mixture of 3a (0.10 mmol, 1.0 equiv) in EtOH (0.50
mL, 0.20 M) under a nitrogen atmosphere at rt were added 4-
fluoroaniline (0.20 mmol, 2.0 equiv) and a drop of 1 N HCl. The
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reaction mixture was heated to reflux and stirred at that
temperature for 1.5 h; it was then cooled to rt. Purification using
automated flash chromatography (MeOH/DCM) was followed
by evaporation, giving 4r as a white solid (0.024 g, 84%). TLC Rf
0.7 (10%MeOH/DCM). LC−MS (ESI)m/z: 287 [M +H]+. 1H
NMR (500 MHz, CDCl3) δ 7.77 (s, 1H), 7.65−7.46 (m, 2H),
7.09−6.89 (m, 2H), 5.95 (d, J = 6.2 Hz, 1H), 5.50 (br s, 2H), 3.71
(br s, 1H), 2.05 (dd, J = 12.9, 4.3 Hz, 2H), 1.78−1.83 (m, 2H),
1.67−1.71 (m, 1H), 1.47−1.33 (m, 2H), 1.22−1.30 (m, 3H). 13C
NMR (126 MHz, CDCl3) δ 161.93, 159.61, 157.69, 135.07,
121.63, 115.39, 50.47, 32.81, 25.49, 24.88.
4-((4-(Cyclohexylamino)pyrimidin-2-yl)amino)benzamide
(4s). To a mixture of 3a (0.10 mmol, 1.0 equiv) in EtOH (0.50
mL, 0.20 M) under a nitrogen atmosphere at rt were added 4-
aminobenzamide (0.20 mmol, 2.0 equiv) and a drop of 1 N HCl.
The reaction mixture was heated to reflux and stirred at that
temperature for 2 h; it was then cooled to rt. Purification using
automated flash chromatography (MeOH/DCM) was followed
by evaporation, giving 4s as a white solid (0.011 g, 35%). TLC Rf
0.5 (10%MeOH/DCM). LC−MS (ESI)m/z: 312 [M +H]+. 1H
NMR (400 MHz, MeOD) δ 7.87−7.79 (m, 4H), 7.75 (d, J = 6.2
Hz, 1H), 6.00 (d, J = 6.1 Hz, 1H), 3.93 (s, 1H), 2.15−2.00 (m,
2H), 1.83−1.88 (m, 2H), 1.71−1.76 (m, 1H), 1.57−1.41 (m,
2H), 1.27−1.34 (m, 3H). 13C NMR (101 MHz, MeOD) δ
172.05, 163.65, 153.57, 145.07, 130.50, 129.60, 119.66, 114.60,
51.24, 33.74, 26.83, 26.36.
N4-Cyclohexyl-N2-(4-(pyridin-2-yl)phenyl)pyrimidine-2,4-
diamine (4t).To amixture of 3a (0.10mmol, 1.0 equiv) in EtOH
(0.50 mL, 0.20 M) under a nitrogen atmosphere at rt were added
4-(2-pyridyl)aniline (0.11 mmol, 1.1 equiv) and a drop of 1 N
HCl. The reaction mixture was heated to reflux and stirred at that
temperature for 3 h; it was then cooled to rt. Purification using
automated flash chromatography (EtOAc/hexanes + 2%MeOH
additive) was followed by evaporation, giving 4t as a colorless oil
(0.002 g, 6%). TLC Rf 0.2 (50% EtOAc/hexanes + 1% MeOH).
LC−MS (ESI) m/z: 346 [M + H]+. 1H NMR (500 MHz,
CDCl3) δ 8.59 (d, J = 4.8 Hz, 1H), 7.89 (d, J = 8.5 Hz, 2H), 7.82
(d, J = 6.2 Hz, 1H), 7.71−7.60 (m, 3H), 7.42−7.25 (m, 1H),
7.16−7.19 (m, 1H), 5.79 (d, J = 5.9 Hz, 1H), 4.76 (s, 1H), 3.84−
3.45 (m, 1H), 2.07−2.10 (m, 2H), 1.67−1.79 (m, 2H), 1.66−
1.56 (m, 1H), 1.45−1.30 (m, 2H), 1.21−1.29 (m, 3H). 13CNMR
(126 MHz, CDCl3) δ 162.02, 158.96, 157.19, 149.55, 140.80,
136.63, 132.88, 127.36, 121.42, 119.86, 118.96, 118.84, 50.15,
33.06, 33.03, 25.60, 24.93.
N4-Cyclohexyl-N2-(4-(pyridin-3-yl)phenyl)pyrimidine-2,4-
diamine (4u). To a mixture of 3a (0.10 mmol, 1.0 equiv) in
EtOH (0.50 mL, 0.20M) under a nitrogen atmosphere at rt were
added 4-pyridin-3-ylaniline (0.11 mmol, 1.1 equiv) and a drop of
1 NHCl. The reaction mixture was heated to reflux and stirred at
that temperature for 4 h; it was then cooled to rt. Purification
using automated flash chromatography (MeOH/DCM) was
followed by evaporation, giving 4u as a colorless oil (0.001 g,
3%). TLC Rf 0.2 (10% MeOH/DCM). LC−MS (ESI) m/z: 346
[M + H]+. 1H NMR (500 MHz, MeOD) δ 10.18−10.05 (m,
1H), 9.83 (d, J = 6.2 Hz, 1H), 8.96 (dd, J = 8.5, 2.1 Hz, 1H),
8.28−8.17 (m, 2H), 7.65 (d, J = 8.2 Hz, 2H), 6.88 (d, J = 8.2 Hz,
2H), 6.72 (d, J = 6.0 Hz, 1H), 4.0−4.11 (m, 1H), 2.10−2.14 (m,
2H), 1.85−1.90 (m, 2H), 1.79−1.67 (m, 1H), 1.48−1.54 (m,
2H), 1.47−1.30 (m, 3H). 13C NMR (126 MHz, MeOD) δ
162.93, 155.06, 154.25, 151.12, 144.26, 141.28, 136.28, 136.14,
127.94, 127.20, 120.72, 114.97, 107.81, 49.92, 31.93, 25.34,
24.63.
2-Chloro-N-methylpyrimidin-4-amine (3b). A mixture of
2,4-dichloropyrimidine 2 (10 mmol, 1.0 equiv) and methylamine
(2.0 M inMeOH) (20mmol, 2.0 equiv) was stirred at rt in DCM
(20mL, 0.50M) in a nitrogen atmosphere. After stirring for 16 h,
the reaction mixture was concentrated to remove volatiles.
Purification using automated flash chromatography (EtOAc/
hexanes + 2% MeOH additive) was followed by evaporation,
giving 3b as a white solid (0.54 g, 38%). TLC Rf 0.4 (70%
EtOAc/hexanes). LC−MS (ESI) m/z: 144 [M + H]+. 1H NMR
(500MHz,MeOD) δ 7.81 (d, J = 6.0Hz, 1H), 6.40 (d, J = 6.4Hz,
1H), 2.92 (s, 3H). 13C NMR (126 MHz, MeOD) δ 164.37,
160.27, 153.78, 104.47, 26.17.
N4-Methyl-N2-(3-(pyridin-3-yl)phenyl)pyrimidine-2,4-dia-
mine (5a). To a mixture of 3b (0.10 mmol, 1.0 equiv) in EtOH
(0.50 mL, 0.20 M) under a nitrogen atmosphere at rt were added
3-(pyridin-3-yl)aniline (0.11 mmol, 1.1 equiv) and a drop of 1 N
HCl. The reaction mixture was heated to reflux and stirred at that
temperature for 3 h; it was then cooled to rt. Purification using
automated flash chromatography (MeOH/DCM) was followed
by evaporation, giving 5a as a colorless oil (0.006 g, 22%). TLCRf
0.4 (10%MeOH/DCM). LC−MS (ESI)m/z: 278 [M +H]+. 1H
NMR (500 MHz, MeOD) δ 8.89−8.77 (m, 1H), 8.52 (d, J = 5.0
Hz, 1H), 8.24−8.05 (m, 2H), 7.87−7.71 (m, 1H), 7.67 (ddd, J =
8.1, 1.8, 0.9 Hz, 1H), 7.52 (dd, J = 8.0, 4.9 Hz, 1H), 7.41 (t, J = 7.9
Hz, 1H), 7.25 (dt, J = 7.6, 1.2 Hz, 1H), 5.98 (d, J = 6.0 Hz, 1H),
2.95 (s, 3H). 13C NMR (126 MHz, MeOD) δ 163.84, 159.69,
153.38, 147.22, 146.94, 141.50, 137.51, 135.13, 129.06, 124.02,
119.79, 118.90, 117.48, 97.46, 26.56.
2-Chloro-N-ethylpyrimidin-4-amine (3c). A mixture of 2,4-
dichloropyrimidine 2 (10 mmol, 1.0 equiv) and ethylamine (2.0
M in THF) (20 mmol, 2.0 equiv) was stirred at rt in MeOH (10
mL, 1.0 M) in a nitrogen atmosphere. After 16 h, the reaction
mixture was concentrated to remove volatiles. Purification using
automated flash chromatography (EtOAc/hexanes + 2%MeOH
additive) was followed by evaporation, giving 3c as a white solid
(0.43 g, 27%). TLC Rf 0.5 (70% EtOAc/hexanes). LC−MS
(ESI) m/z: 160 [M + H]+. 1H NMR (500 MHz, CDCl3) δ 8.04
(br s, 1H), 6.26 (d, J = 5.9 Hz, 1H), 5.41 (br s, 1H), 3.38 (br s,
2H), 1.28 (t, J = 7.3 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ
163.55, 160.58, 157.26, 99.99, 36.48, 14.36.
N4-Ethyl-N2-(3-(pyridin-3-yl)phenyl)pyrimidine-2,4-dia-
mine (5b). To a mixture of 3c (0.10 mmol, 1.0 equiv) in EtOH
(0.50 mL, 0.20 M) under a nitrogen atmosphere at rt were added
3-(pyridin-3-yl)aniline (0.11 mmol, 1.1 equiv) and a drop of 1 N
HCl. The reaction mixture was heated to reflux and stirred at that
temperature for 3 h; it was then cooled to rt. Purification using
automated flash chromatography (MeOH/DCM) was followed
by evaporation, giving 5b as a colorless oil (0.003 g, 10%). TLC
Rf 0.1 (5% MeOH/DCM). LC−MS (ESI) m/z: 292 [M + H]+.
1H NMR (500 MHz, MeOD) δ 8.84 (s, 1H), 8.55 (s, 1H), 8.18
(s, 1H), 8.13 (dt, J = 8.1, 1.8 Hz, 1H), 7.78 (s, 1H), 7.68−7.59
(m, 1H), 7.55 (dd, J = 8.0, 4.8 Hz, 1H), 7.42 (t, J = 7.9 Hz, 1H),
7.26 (dt, J = 7.7, 1.2 Hz, 1H), 5.97 (d, J = 5.4 Hz, 1H), 3.56−3.38
(m, 2H), 1.23 (t, J = 7.2 Hz, 3H). 13C NMR (126 MHz, MeOD)
δ 163.10, 147.24, 146.98, 141.55, 137.81, 137.57, 135.18, 129.04,
124.04, 119.79, 118.83, 117.43, 35.14, 13.49.
2-Chloro-N-propylpyrimidin-4-amine (3d). Amixture of 2,4-
dichloropyrimidine 2 (10 mmol, 1.0 equiv) and cyclopentyl-
amine (20 mmol, 2.0 equiv) was stirred at rt in DCM (20 mL,
0.50 M) in a nitrogen atmosphere. After stirring for 16 h, the
reaction mixture was concentrated. Purification using automated
flash chromatography (EtOAc/hexanes) was followed by
evaporation, giving 3d as a colorless oil (0.84 g, 49%). TLC Rf
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0.3 (40% EtOAc/hexanes). LC−MS (ESI) m/z: 174 [M + H]+.
1H NMR (500 MHz, CDCl3) δ 8.04 (br s, 1H), 6.27 (d, J = 6.0
Hz, 1H), 5.54 (br s, 1H), 3.28 (br s, 2H), 1.66 (q, J = 7.3 Hz, 2H),
1.00 (t, J = 7.4 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 163.74,
160.55, 157.72, 99.81, 43.44, 22.35, 11.32.
N4-Propyl-N2-(3-(pyridin-3-yl)phenyl)pyrimidine-2,4-dia-
mine (5c). To a mixture of 3d (0.10 mmol, 1.0 equiv) in EtOH
(0.50 mL, 0.20 M) under a nitrogen atmosphere at rt were added
3-(pyridin-3-yl)aniline (0.11 mmol, 1.1 equiv) and a drop of 1 N
HCl. The reaction mixture was heated to reflux and stirred at that
temperature for 3 h; it was then cooled to rt. Purification using
automated flash chromatography (MeOH/DCM) was followed
by evaporation, giving 5c as a colorless oil (0.005 g, 16%). TLC Rf
0.4 (10%MeOH/DCM). LC−MS (ESI)m/z: 306 [M +H]+. 1H
NMR (500 MHz, MeOD) δ 8.82 (s, 1H), 8.58−8.47 (m, 1H),
8.21−8.07 (m, 2H), 7.76 (s, 1H), 7.69−7.61 (m, 1H), 7.53 (dd, J
= 7.9, 4.8 Hz, 1H), 7.41 (t, J = 7.9 Hz, 1H), 7.25 (dt, J = 7.7, 1.2
Hz, 1H), 5.97 (d, J = 5.8 Hz, 1H), 3.37 (s, 2H), 1.62 (q, J = 7.3
Hz, 2H), 0.92 (t, J = 7.3 Hz, 3H). 13C NMR (126 MHz, MeOD)
δ 163.26, 159.66, 153.40, 147.22, 147.00, 141.51, 137.76, 137.56,
135.19, 129.02, 124.02, 119.84, 118.89, 117.53, 97.60, 42.24,
22.19, 10.38.
N-Butyl-2-chloropyrimidin-4-amine (3e).To a suspension of
2,4-dichloropyrimidine 2 (10 mmol, 1.0 equiv) in DCM (20 mL,
0.50 M) was added butylamine (20 mmol, 2.0 equiv) under a
nitrogen atmosphere at rt. After stirring for 16 h, the reaction
mixture was concentrated. Purification using automated flash
chromatography (EtOAc/hexanes) was followed by evaporation,
giving 3e as a white solid (0.96 g, 52%). TLC Rf 0.25 (30%
EtOAc/hexanes). LC−MS (ESI) m/z: 188 [M + H]+. 1H NMR
(400 MHz, CDCl3) δ 8.04 (br s, 1H), 6.25 (d, J = 5.9 Hz, 1H),
5.46 (br s, 1H), 3.31 (br s, 2H), 1.71−1.51 (m, 2H), 1.51−1.33
(m, 2H), 0.97 (t, J = 7.3 Hz, 3H). 13CNMR (101MHz, CDCl3) δ
163.70, 160.62, 156.38, 41.42, 31.11, 19.97, 13.71.
N4-Butyl-N2-(3-(pyridin-3-yl)phenyl)pyrimidine-2,4-dia-
mine (5d). To a mixture of 3e (0.10 mmol, 1.0 equiv) in EtOH
(0.50 mL, 0.20 M) under a nitrogen atmosphere at rt were added
3-(pyridin-3-yl)aniline (0.11 mmol, 1.1 equiv) and a drop of 1 N
HCl. The reaction mixture was heated to reflux and stirred at that
temperature for 3 h; it was then cooled to rt. Purification using
automated flash chromatography (MeOH/DCM) was followed
by evaporation, giving 5d as a colorless oil (0.006 g, 19%). TLC
Rf 0.4 (10%MeOH/DCM). LC−MS (ESI) m/z: 320 [M + H]+.
1HNMR (400MHz,MeOD) δ 8.70 (s, 1H), 8.48−8.33 (m, 1H),
8.07−7.95 (m, 2H), 7.63 (s, 1H), 7.53 (dd, J = 8.2, 2.1 Hz, 1H),
7.39−7.43 (m, 1H), 7.29 (t, J = 7.9 Hz, 1H), 7.13 (d, J = 7.7 Hz,
1H), 5.85 (d, J = 6.0 Hz, 1H), 3.28 (s, 2H), 1.43−1.50 (m, 2H),
1.21−1.26 (m, 2H), 0.79 (t, J = 7.4 Hz, 3H). 13C NMR (101
MHz, MeOD) δ 164.65, 161.00, 148.65, 148.45, 142.88, 139.17,
136.60, 130.43, 125.42, 121.32, 120.36, 119.03, 117.61, 41.58,
32.56, 21.21, 14.19.
2-Chloro-N-isopropylpyrimidin-4-amine (3f). To a suspen-
sion of 2,4-dichloropyrimidine 2 (10 mmol, 1.0 equiv) in DCM
(20 mL, 0.50 M) under a nitrogen atmosphere was added
isopropylamine (20 mmol, 2.0 equiv) at rt. After stirring for 16 h,
the reaction mixture was concentrated. Purification using
automated flash chromatography (EtOAc/hexanes) was fol-
lowed by evaporation, giving 3f as a colorless oil (1.0 g, 60%).
TLC Rf 0.10 (30% EtOAc/hexanes). LC−MS (ESI) m/z: 174
[M +H]+. 1HNMR (400MHz, CDCl3) δ 8.02 (s, 1H), 6.23 (d, J
= 5.9 Hz, 1H), 5.10 (br s, 1H), 3.94 (br s, 1H), 1.27 (d, J = 6.5 Hz,
6H). 13C NMR (126 MHz, CDCl3) δ 162.81, 160.84, 157.19,
100.94, 43.25, 22.52.
N4-Isopropyl-N2-(3-(pyridin-3-yl)phenyl)pyrimidine-2,4-di-
amine (5e). To a mixture of 3f (0.105 mmol, 1.00 equiv) in
EtOH (0.500 mL, 0.210 M) under a nitrogen atmosphere at rt
were added 3-(pyridin-3-yl)aniline (0.115mmol, 1.10 equiv) and
a drop of 1 NHCl. The reaction mixture was heated to reflux and
stirred at that temperature for 3 h; it was then cooled to rt.
Purification using automated flash chromatography (MeOH/
DCM) was followed by evaporation, giving 5e as a colorless oil
(0.005 g, 16%). TLC Rf 0.5 (10% MeOH/DCM). HRMS (ESI)
m/z: calcd for [M + H]+ 306.1718, found 306.1720. 1H NMR
(500 MHz, CDCl3) δ 8.87 (s, 1H), 8.59 (s, 1H), 8.05−7.82 (m,
3H), 7.55 (d, J = 5.0 Hz, 1H), 7.35−7.41 (m, 3H), 7.20 (d, J =
10.0 Hz, 1H), 5.85 (d, J = 5.7 Hz, 1H), 4.72 (s, 1H), 4.06 (s, 1H),
1.25 (d, J = 6.4 Hz, 6H). 13C NMR (126 MHz, CDCl3) δ 162.16,
159.77, 155.62, 148.38, 148.36, 141.01, 138.40, 136.95, 134.44,
129.41, 123.46, 120.54, 118.80, 117.78, 96.46, 42.81, 22.80.
N-(tert-Butyl)-2-chloropyrimidin-4-amine (3g). Amixture of
2,4-dichloropyrimidine 2 (10 mmol, 1.0 equiv) and tert-
butylamine (20 mmol, 2.0 equiv) was stirred at rt in DCM (20
mL, 0.50 M) under a nitrogen atmosphere for 16 h. The reaction
mixture was then concentrated to remove volatiles. Purification
using automated flash chromatography (EtOAc/hexanes) was
followed by evaporation, giving 3g as a white oil (0.017 g, 1%).
TLC Rf 0.3 (40% EtOAc/hexanes). LC−MS (ESI)m/z: 186 [M
+ H]+. 1H NMR (500 MHz, CDCl3) δ 7.97 (d, J = 6.0 Hz, 1H),
6.25 (br s, 1H), 5.07 (br s, 1H), 1.44 (s, 9H). 13C NMR (126
MHz, CDCl3) δ 162.88, 160.49, 156.53, 103.33, 51.87, 28.90.
N4-(tert-Butyl)-N2-(3-(pyridin-3-yl)phenyl)pyrimidine-2,4-
diamine (5f). To a mixture of 3g (0.081 mmol, 1.0 equiv) in
EtOH (0.50 mL, 0.16M) under a nitrogen atmosphere at rt were
added 3-(pyridin-3-yl)aniline (0.089 mmol, 1.1 equiv) and a
drop of 1 N HCl. The reaction mixture was heated to reflux and
stirred at that temperature for 3 h; it was then cooled to rt.
Purification using automated flash chromatography (MeOH/
DCM) was followed by evaporation, giving 5f as an orange oil
(0.004 g, 16%). TLC Rf 0.3 (5% MeOH/DCM). LC−MS (ESI)
m/z: 319 [M + H]+. 1H NMR (500 MHz, CDCl3) δ 8.91 (br s,
1H), 8.63 (br s, 1H), 8.08−7.73 (m, 3H), 7.58 (d, J = 8.2 Hz,
1H), 7.40−7.44 (m, 3H), 7.24 (d, J = 5.0 Hz, 1H), 5.89 (d, J = 5.4
Hz, 1H), 4.85 (s, 1H), 1.46 (s, 9H). 13C NMR (126 MHz,
CDCl3) δ 162.37, 158.85, 153.78, 148.44, 140.43, 138.58, 134.51,
129.44, 123.54, 121.10, 119.34, 118.31, 98.58, 51.59, 29.14.
2-Chloro-N-(1-methoxypropan-2-yl)pyrimidin-4-amine
(3h). A mixture of 2,4-dichloropyrimidine 2 (5.0 mmol, 1.0
equiv), 1-methoxypropan-2-amine HCl (7.5 mmol, 1.5 equiv),
and triethylamine (10.5 mmol, 2.1 equiv) was stirred at rt in
DCM (10 mL, 0.50 M) in a nitrogen atmosphere. After 16 h, the
reaction mixture was concentrated to remove volatiles. To the
crude residue was added water (10 mL), and the aqueous portion
was extracted into EtOAc (3 × 10 mL). The combined organics
were dried over magnesium sulfate, filtered, and concentrated.
Purification using automated flash chromatography (EtOAc/
hexanes) was followed by evaporation, giving 3h as a colorless oil
(0.29 g, 29%). TLC Rf 0.3 (60% EtOAc/hexanes). LC−MS
(ESI) m/z: 204 [M + H]+. 1H NMR (500 MHz, CDCl3) δ 8.00
(d, J = 6.2 Hz, 1H), 6.26 (d, J = 6.0 Hz, 1H), 5.44 (br s, 1H), 4.21
(br s, 1H), 3.56−3.31 (m, 5H), 1.28 (d, J = 6.7 Hz, 3H). 13C
NMR (126 MHz, CDCl3) δ 162.99, 160.71, 156.53, 104.44,
75.32, 59.18, 46.45, 17.43.
N4-(1-Methoxypropan-2-yl)-N2-(3-(pyridin-3-yl)phenyl)-
pyrimidine-2,4-diamine (5g). To a mixture of 3h (0.10 mmol,
1.0 equiv) in EtOH (0.50 mL, 0.20 M) under a nitrogen
atmosphere at rt were added 3-(pyridin-3-yl)aniline (0.11 mmol,
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1.1 equiv) and a drop of 1 N HCl. The reaction mixture was
heated to reflux and stirred at that temperature for 3 h; it was then
cooled to rt. Purification using automated flash chromatography
(MeOH/DCM) was followed by evaporation, giving 5g as a
colorless oil (0.010 g, 30%). TLC Rf 0.2 (5% MeOH/DCM).
LC−MS (ESI) m/z: 336 [M + H]+. 1H NMR (500 MHz,
MeOD) δ 8.83 (s, 1H), 8.54 (d, J = 4.9 Hz, 1H), 8.11−8.14 (m,
2H), 7.76 (d, J = 5.7 Hz, 1H), 7.63 (d, J = 5.0 Hz, 1H), 7.54 (ddd,
J = 7.9, 4.9, 0.9 Hz, 1H), 7.41 (t, J = 7.9 Hz, 1H), 7.26 (d, J = 5.0
Hz, 1H), 5.99 (d, J = 6.0 Hz, 1H), 4.38 (s, 1H), 3.42 (ddd, J =
49.5, 9.4, 5.6 Hz, 2H), 3.33 (s, 3H), 1.23 (d, J = 6.7 Hz, 3H). 13C
NMR (126 MHz, MeOD) δ 162.75, 159.70, 153.82, 147.24,
147.00, 141.52, 137.59, 135.24, 129.04, 124.01, 119.84, 118.89,
117.51, 97.54, 75.41, 57.78, 45.46, 16.36.
Methyl (2-chloropyrimidin-4-yl)-L-alaninate (3i). A mixture
of 2,4-dichloropyrimidine 2 (10 mmol, 1.0 equiv), H-Ala-OMe-
HCl (10 mmol, 1.0 equiv), and triethylamine (12 mmol, 1.2
equiv) was stirred at rt in DCM (20 mL, 0.50 M) in a nitrogen
atmosphere. After stirring for 16 h, the reaction mixture was
concentrated to remove volatiles. To the crude residue was
added water (10 mL), and the crude was extracted into EtOAc (3
× 10 mL). The combined organic phases were dried over
magnesium sulfate, filtered, and concentrated. Purification using
automated flash chromatography (EtOAc/hexanes) was fol-
lowed by evaporation, giving 3i as a colorless oil (0.13 g, 6%).
TLC Rf 0.2 (40% EtOAc/hexanes). LC−MS (ESI) m/z: 218 [M
+ H]+. [α]D
20 = −20 (c 0.00066, CHCl3). 1H NMR (500 MHz,
CDCl3) δ 8.15−7.97 (m, 1H), 6.33 (d, J = 5.4Hz, 1H), 5.69 (br s,
1H), 4.73 (br s, 1H), 3.82 (s, 3H), 1.54 (d, J = 5.0 Hz, 3H). 13C
NMR (126 MHz, CDCl3) δ 173.35, 162.39, 160.59, 160.54,
156.33, 104.28, 52.74, 49.33, 18.31.
Methyl (2-((3-(pyridin-3-yl)phenyl)amino)pyrimidin-4-yl)-L-
alaninate (5h). To a mixture of 3i (0.30 mmol, 1.0 equiv) in
EtOH (1.5 mL, 0.20 M) under a nitrogen atmosphere at rt were
added 3-(pyridin-3-yl)aniline (0.33 mmol, 1.1 equiv) and a drop
of 1 NHCl. The reaction mixture was heated to reflux and stirred
at that temperature for 3 h; it was then cooled to rt. Purification
using automated flash chromatography (MeOH/DCM) was
followed by evaporation, giving 5h as an orange foam (0.024 g,
23%). TLC Rf 0.1 (5% MeOH/DCM). LC−MS (ESI) m/z: 350
[M + H]+. [α]D
20 = −36 (c 0.000044, CHCl3). 1H NMR (500
MHz, MeOD) δ 8.85 (s, 1H), 8.54 (d, J = 4.9 Hz, 1H), 8.14 (dt, J
= 8.0, 1.9 Hz, 1H), 7.97 (t, J = 2.0 Hz, 1H), 7.82 (d, J = 5.9 Hz,
1H), 7.66 (ddd, J = 8.4, 2.2, 1.0 Hz, 1H), 7.55 (dd, J = 7.9, 4.9 Hz,
1H), 7.42 (t, J = 7.9 Hz, 1H), 7.28 (ddd, J = 7.7, 1.8, 1.0 Hz, 1H),
6.09 (d, J = 5.9 Hz, 1H), 4.68 (d, J = 7.3 Hz, 1H), 3.57 (s, 3H),
1.48 (d, J = 7.3 Hz, 3H). 13C NMR (126MHz, MeOD) δ 174.42,
162.57, 159.21, 153.59, 147.25, 147.05, 141.08, 137.64, 135.25,
129.08, 124.01, 120.21, 119.23, 117.75, 97.64, 51.11, 49.18,
48.10, 16.28.
(2-((3-(Pyridin-3-yl)phenyl)amino)pyrimidin-4-yl)-L-ala-
nine (5i). To 5h (0.043 mmol, 1.0 equiv) in 0.72 mL (0.060 M)
of THF/water (5:1) at rt under a nitrogen atmosphere was added
a 1 N NaOH solution (0.13 mmol, 3.0 equiv). The reaction
mixture was stirred at 80 °C for 3 h; it was then cooled to rt and
concentrated to remove volatiles. The residue was diluted with
water (1 mL) and then adjusted to pH 4 with 1 N HCl. The
precipitated solid was filtered and washed with water, providing
5i as a white solid (0.007 g, 49%). LC−MS (ESI)m/z: 336 [M +
H]+. [α]D
20 = −55 (c 0.000024, CHCl3). 1H NMR (500 MHz,
MeOD) δ 8.81 (s, 1H), 8.54 (s, 1H), 8.16−8.06 (m, 1H), 7.72
(dd, J = 5.6, 2.8 Hz, 2H), 7.64 (d, J = 6.8 Hz, 1H), 7.54 (dd, J =
8.0, 4.9 Hz, 1H), 7.47 (t, J = 8.1 Hz, 1H), 7.37 (dt, J = 7.8, 1.4 Hz,
1H), 6.18 (d, J = 6.7 Hz, 1H), 4.51 (s, 1H), 1.49 (d, J = 7.2 Hz,
3H). 13C NMR (126 MHz, MeOD) δ 176.99, 162.40, 155.33,
147.46, 146.98, 139.06, 137.96, 136.98, 135.26, 129.59, 124.10,
122.01, 120.78, 119.07, 98.50, 51.06, 16.82.
(S)-N-(sec-Butyl)-2-chloropyrimidin-4-amine (3j). To a
suspension of 2,4-dichloropyrimidine 2 (2.0 mmol, 1.0 equiv)
in DCM (5.0 mL, 0.40 M) under a nitrogen atmosphere was
added (S)-(+)-2-aminobutane (4.0 mmol, 2.0 equiv) at rt. After
stirring for 6 h, the reaction mixture was concentrated.
Purification using automated flash chromatography (EtOAc/
hexanes) was followed by evaporation, giving 3j as a colorless oil
(0.14 g, 37%). TLC Rf 0.25 (30% EtOAc/hexanes). LC−MS
(ESI) m/z: 188 [M + H]+. [α]D
20 = 29 (c 0.0011, CHCl3).
1H
NMR (500 MHz, MeOD) δ 7.79 (d, J = 5.0 Hz, 1H), 6.36 (d, J =
5.0 Hz, 1H), 4.04−4.09 (m,1H), 1.64−1.49 (m, 2H), 1.19 (d, J =
6.6 Hz, 3H), 0.95 (t, J = 7.4 Hz, 3H). 13C NMR (126 MHz,
MeOD) δ 163.46, 160.18, 153.91, 104.38, 28.82, 18.75, 9.38.
(S)-N4-(sec-Butyl)-N2-(3-(pyridin-3-yl)phenyl)pyrimidine-
2,4-diamine (5j). To a mixture of 3j (0.10 mmol, 1.0 equiv) in
EtOH (0.50 mL, 0.20M) under a nitrogen atmosphere at rt were
added 3-(pyridin-3-yl)aniline (0.11 mmol, 1.1 equiv) and a drop
of 1 NHCl. The reaction mixture was heated to reflux and stirred
at that temperature for 4 h; it was then cooled to rt. Purification
using automated flash chromatography (MeOH/DCM) was
followed by evaporation, giving 5j as a yellow oil (0.007 g, 22%).
TLC Rf 0.5 (10%MeOH/DCM). LC−MS (ESI)m/z: 320 [M +
H]+. [α]D
20 = 11 (c 0.000073, CHCl3).
1H NMR (500 MHz,
CDCl3) δ 8.86 (s, 1H), 8.58 (d, J = 4.5 Hz, 1H), 8.01−7.80 (m,
3H), 7.57 (d, J = 5.0 Hz, 1H), 7.49−7.29 (m, 3H), 7.19 (d, J = 5.8
Hz, 1H), 5.85 (d, J = 5.8 Hz, 1H), 4.77 (br s, 1H), 3.85 (br s, 1H),
1.53−1.59 (m, 2H), 1.20 (d, J = 6.4 Hz, 3H), 0.92 (t, J = 7.4 Hz,
3H). 13C NMR (126 MHz, CDCl3) δ 162.43, 159.48, 155.08,
148.41, 140.82, 138.47, 136.91, 134.45, 129.43, 123.46, 120.68,
118.81, 117.79, 96.43, 48.24, 29.66, 20.27, 10.36.
(R)-N-(sec-Butyl)-2-chloropyrimidin-4-amine (3k). To a
suspension of 2,4-dichloropyrimidine 2 (1.0 mmol, 1.0 equiv)
in DCM (3.0 mL, 0.33M) under a nitrogen atmosphere was
added (R)-(−)-2-aminobutane (2.0 mmol, 2.0 equiv) at rt. After
stirring for 6 h, the reaction mixture was concentrated.
Purification using automated flash chromatography (EtOAc/
hexanes) was followed by evaporation, giving 3k as a colorless oil
(0.071 g, 38%). TLC Rf 0.25 (30% EtOAc/hexanes). LC−MS
(ESI)m/z: 188 [M + H]+. [α]D
20 = −45 (c 0.00048, CHCl3). 1H
NMR (500 MHz, MeOD) δ 7.79 (d, J = 6.1 Hz, 1H), 6.37 (d, J =
6.7 Hz, 1H), 4.17−3.96 (m, 1H), 1.65−1.48 (m, 2H), 1.19 (d, J =
6.6 Hz, 3H), 0.96 (t, J = 7.4 Hz, 3H). 13C NMR (126 MHz,
MeOD) δ 163.47, 160.19, 153.91, 104.38, 48.21, 28.81, 18.74,
9.37.
(R)-N4-(sec-Butyl)-N2-(3-(pyridin-3-yl)phenyl)pyrimidine-
2,4-diamine (5k). To a mixture of 3k (0.10 mmol, 1.0 equiv) in
EtOH (0.50 mL, 0.20M) under a nitrogen atmosphere at rt were
added 3-(pyridin-3-yl)aniline (0.11 mmol, 1.1 equiv) and a drop
of 1 NHCl. The reaction mixture was heated to reflux and stirred
at that temperature for 2 h; it was then cooled to rt. Purification
using automated flash chromatography (MeOH/DCM) was
followed by evaporation, giving 5k as a colorless oil (0.003 g,
9%). TLC Rf 0.3 (80% EtOAc/hexanes). LC−MS (ESI) m/z:
320 [M + H]+. [α]D
20 = −10 (c 0.000033, CHCl3). 1H NMR
(500 MHz, CDCl3) δ 8.87 (s, 1H), 8.59 (s, 1H), 7.96 (s, 2H),
7.89 (dt, J = 7.8, 1.8 Hz, 1H), 7.57 (ddd, J = 8.1, 2.0, 1.0 Hz, 1H),
7.42−7.32 (m, 2H), 7.22−7.15 (m, 2H), 5.85 (d, J = 5.6 Hz, 1H),
4.64 (br s, 1H), 3.86 (br s, 1H), 1.66−1.47 (m, 2H), 1.21 (d, J =
6.5 Hz, 3H), 0.93 (t, J = 7.4 Hz, 3H). 13C NMR (126 MHz,
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CDCl3) δ 162.43, 159.67, 155.70, 148.44, 148.42, 140.87, 138.49,
136.94, 134.44, 129.44, 123.46, 120.63, 118.72, 117.72, 96.94,
48.20, 29.69, 20.30, 10.36.
2-Chloro-N-cyclopropylpyrimidin-4-amine (3l). A mixture
of 2,4-dichloropyrimidine 2 (10 mmol, 1.0 equiv) and cyclo-
propylamine (10 mmol, 1.0 equiv) was stirred at rt in DCM (20
mL, 0.50M) in a nitrogen atmosphere. After stirring for 16 h, the
reaction mixture was concentrated to remove volatiles.
Purification using automated flash chromatography (EtOAc/
hexanes) was followed by evaporation, giving 3l as a white solid
(0.39 g, 23%). TLC Rf 0.3 (40% EtOAc/hexanes). LC−MS
(ESI) m/z: 172 [M + H]+. 1H NMR (500 MHz, CDCl3) δ 8.15
(d, J = 5.9 Hz, 1H), 6.77−6.48 (m, 1H), 5.74 (br s, 1H), 2.59 (br
s, 1H), 1.00−0.83 (m, 2H), 0.72−0.54 (m, 2H). 13C NMR (126
MHz, CDCl3) δ 165.25, 160.30, 157.64, 101.64, 23.46, 7.71.
N4-Cyclopropyl-N2-(3-(pyridin-3-yl)phenyl)pyrimidine-2,4-
diamine (5l). To a mixture of 3l (0.10 mmol, 1.0 equiv) in EtOH
(0.50 mL, 0.20 M) under a nitrogen atmosphere at rt were added
3-(pyridin-3-yl)aniline (0.11 mmol, 1.1 equiv) and a drop of 1 N
HCl. The reaction mixture was heated to reflux and stirred at that
temperature for 3 h; it was then cooled to rt. Purification using
automated flash chromatography (MeOH/DCM) was followed
by evaporation, giving 5l as a colorless oil (0.004 g, 13%). TLC Rf
0.2 (5% MeOH/DCM). LC−MS (ESI) m/z: 304 [M + H]+. 1H
NMR (500 MHz, CDCl3) δ 8.87 (d, J = 2.6 Hz, 1H), 8.58 (d, J =
5.0 Hz, 1H), 8.05 (d, J = 5.0 Hz, 1H), 7.93 (s, 1H), 7.86−7.88 (m
1H), 7.56 (d, J = 8.3 Hz, 1H), 7.41−7.31 (m, 2H), 7.19 (d, J = 7.6
Hz, 1H), 7.13 (s, 1H), 6.32−6.08 (m, 1H), 5.22 (s, 1H), 2.57 (br
s, 1H), 0.84−0.78 (m, 2H), 0.62−0.56 (m, 2H). 13C NMR (126
MHz, CDCl3) δ 164.36, 159.65, 156.84, 148.46, 148.43, 140.76,
138.48, 136.86, 134.44, 129.45, 123.49, 120.73, 118.81, 117.77,
95.85, 23.46, 7.59.
2-Chloro-N-(1-(trifluoromethyl)cyclopropyl)pyrimidin-4-
amine (3m). A mixture of 2,4-dichloropyrimidine 2 (2.0 mmol,
1.0 equiv) and 1-(trifluoromethyl)cyclopropanamine (2.5 mmol,
1.25 equiv) was stirred in NMP (1.0 mL, 2.0 M) under
microwave irradiation at 140 °C and 24 W for 1 h. Purification
using automated flash chromatography (EtOAc/hexanes) was
followed by evaporation, giving 3m as a white solid (0.013 g, 3%).
TLC Rf 0.4 (30% EtOAc/hexanes). LC−MS (ESI) m/z: 238 [M
+ H]+. 1H NMR (500 MHz, CDCl3) δ 8.24 (d, J = 5.8 Hz, 1H),
6.68 (d, J = 5.8 Hz, 1H), 5.85 (br s, 1H), 1.56−1.45 (m, 2H),
1.17−1.19 (m, 2H). 13C NMR (126 MHz, CDCl3) δ 164.16,
160.60, 158.41, 125.15 (q, J = 277 Hz, CF3), 119.37, 102.39,
34.46, 34.16, 33.86, 12.67, 12.66, 12.64. 19F NMR (471 MHz,
CDCl3) δ −73.26.
N2-(3-(Pyridin-3-yl)phenyl)-N4-(1-(trifluoromethyl)-
cyclopropyl)pyrimidine-2,4-diamine (5m). To a mixture of 3m
(0.038 mmol, 1.0 equiv) in EtOH (0.50 mL, 0.76M) under a
nitrogen atmosphere at rt was added 3-(pyridin-3-yl)aniline
(0.045 mmol, 1.2 equiv). The reaction mixture was heated to
reflux and stirred at that temperature for 3 h; it was then cooled to
rt. Purification using automated flash chromatography (MeOH/
DCM) was followed by evaporation, giving 5m as a colorless oil
(0.002 g, 14%). TLC Rf 0.5 (10%MeOH/DCM). LC−MS (ESI)
m/z: 372 [M +H]+. 1HNMR (500MHz, CDCl3) δ 8.88 (s, 1H),
8.61 (s, 1H), 8.10 (d, J = 5.8 Hz, 1H), 7.95−7.82 (m, 2H), 7.56−
7.58 (m, 1H), 7.41 (t, J = 7.9 Hz, 2H), 7.25−7.18 (m, 1H), 6.99
(s, 1H), 6.21 (d, J = 5.6 Hz, 1H), 5.35 (s, 1H), 1.45−1.36 (m,
2H), 1.22−1.12 (m, 2H). 13C NMR (126 MHz, CDCl3) δ
163.00, 159.67, 157.42, 148.46, 140.39, 138.63, 134.45, 129.50,
125.46 (q, J = 275.94, CF3), 122.16, 121.12, 118.96, 117.91,
96.47, 34.56, 34.25, 33.95, 33.65, 12.74. 19F NMR (471 MHz,
CDCl3) δ −73.18.
2-Chloro-N-cyclobutylpyrimidin-4-amine (3n). A mixture of
2,4-dichloropyrimidine 2 (10 mmol, 1.0 equiv) and cyclobutyl-
amine (10 mmol, 1.0 equiv) was stirred at rt in DCM (20 mL,
0.50 M) in a nitrogen atmosphere. After stirring for 16 h, the
reaction mixture was concentrated to remove volatiles.
Purification using automated flash chromatography (EtOAc/
hexanes) was followed by evaporation, giving 3n as a white solid
(0.059 g, 3%). TLC Rf 0.3 (40% EtOAc/hexanes). LC−MS
(ESI) m/z: 184 [M + H]+. 1H NMR (500 MHz, CDCl3) δ 8.04
(d, J = 10.9 Hz, 1H), 6.21 (d, J = 10.0 Hz, 1H), 5.48 (br s, 1H),
4.01 (br s, 1H), 2.57−2.40 (m, 2H), 1.92−1.97 (m, 2H), 1.90−
1.74 (m, 2H). 13C NMR (126 MHz, CDCl3) δ 162.57, 160.51,
157.78, 100.35, 46.73, 31.27, 30.75, 15.16.
N4-Cyclobutyl-N2-(3-(pyridin-3-yl)phenyl)pyrimidine-2,4-
diamine (5n). To a mixture of 3n (0.10 mmol, 1.0 equiv) in
EtOH (0.50 mL, 0.20M) under a nitrogen atmosphere at rt were
added 3-(pyridin-3-yl)aniline (0.11 mmol, 1.1 equiv) and a drop
of 1 NHCl. The reaction mixture was heated to reflux and stirred
at that temperature for 3 h; it was then cooled to rt. Purification
using automated flash chromatography (MeOH/DCM) was
followed by evaporation, giving 5n as a yellow oil (0.002 g, 6%).
TLC Rf 0.1 (5% MeOH/DCM). LC−MS (ESI) m/z: 318 [M +
H]+. 1HNMR (500MHz, MeOD) δ 8.85 (s, 1H), 8.62−8.49 (m,
1H), 8.35−8.14 (m, 1H), 8.13 (dt, J = 8.0, 1.9 Hz, 1H), 7.77 (s,
1H), 7.54−7.60 (m, 2H), 7.42 (t, J = 7.9 Hz, 1H), 7.26 (d, J = 7.6,
1H), 5.94 (d, J = 5.9 Hz, 1H), 4.40−4.56 (m, 1H), 2.42−2.25 (m,
2H), 1.92−2.01 (m, 2H), 1.79−1.54 (m, 2H). 13C NMR (126
MHz, MeOD) δ 162.15, 159.43, 153.31, 147.28, 147.04, 141.37,
137.82, 137.63, 135.20, 129.03, 124.01, 120.00, 118.93, 117.64,
97.37, 45.88, 30.32, 14.57.
2-Chloro-N-cyclopentylpyrimidin-4-amine (3o). A mixture
of 2,4-dichloropyrimidine 2 (10 mmol, 1.0 equiv) and cyclo-
pentylamine (20 mmol, 2.0 equiv) was stirred at rt in DCM (20
mL, 0.50 M) in a nitrogen atmosphere. After 16 h, the reaction
mixture was concentrated. Purification using automated flash
chromatography (EtOAc/hexanes) followed by evaporation
gave 3o as a yellow oil (1.12 g, 57%). TLC Rf 0.25 (40%
EtOAc/hexanes). LC−MS (ESI) m/z: 200 [M + H]+. 1H NMR
(500 MHz, CDCl3) δ 8.03 (d, J = 11.7 Hz, 1H), 6.32 (d, J = 6.3
Hz, 1H), 5.46 (br s, 1H), 3.93 (br s, 1H), 2.19−1.94 (m, 2H),
1.87−1.63 (m, 4H), 1.51−1.56 (m, 2H). 13C NMR (126 MHz,
CDCl3) δ 163.22, 160.56, 157.25, 100.46, 53.12, 33.08, 23.66.
N4-Cyclopentyl-N2-(3-(pyridin-3-yl)phenyl)pyrimidine-2,4-
diamine (5o). To a mixture of 3o (0.10 mmol, 1.0 equiv) in
EtOH (0.50 mL, 0.20M) under a nitrogen atmosphere at rt were
added 3-(pyridin-3-yl)aniline (0.11 mmol, 1.1 equiv) and a drop
of 1 NHCl. The reaction mixture was heated to reflux and stirred
at that temperature for 3 h; it was then cooled to rt. Purification
using automated flash chromatography (MeOH/DCM) was
followed by evaporation, giving 5o as a white oil (0.005 g, 15%).
TLC Rf 0.5 (10%MeOH/DCM). LC−MS (ESI)m/z: 332 [M +
H]+. 1HNMR (400MHz, MeOD) δ 8.81 (s, 1H), 8.53 (d, J = 5.1
Hz, 1H), 8.21 (br s, 1H), 8.09 (d, J = 7.5 Hz, 1H), 7.74 (s, 1H),
7.67−7.56 (m, 1H), 7.51−7.54 (m, 1H), 7.40 (t, J = 7.9 Hz, 1H),
7.23 (dd, J = 7.6, 1.9 Hz, 1H), 5.96 (d, J = 5.8 Hz, 1H), 4.30 (s,
1H), 1.96−2.01 (m, 2H), 1.68−1.75 (m, 2H), 1.45−1.53 (m,
4H). 13C NMR (101 MHz, MeOD) δ 164.22, 161.02, 148.64,
148.46, 142.94, 139.27, 139.02, 136.62, 130.40, 125.39, 121.27,
120.25, 118.99, 53.54, 33.77, 24.70.
N-(2-Chloropyrimidin-4-yl)-O-methylhydroxylamine (3p).
A mixture of 2,4-dichloropyrimidine 2 (10 mmol, 1.0 equiv),
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O-methylhydroxylamine HCl (15 mmol, 1.5 equiv), and
triethylamine (20 mmol, 2.0 equiv) was stirred at rt in a 0.50
M mixture of DCM (10 mL) and MeOH (10 mL) under a
nitrogen atmosphere for 16 h. The reaction mixture was then
concentrated to remove volatiles. To the crude residue was
added water (10 mL), and then, the crude was extracted into
EtOAc (3 × 10 mL). The organic phase was dried over
magnesium sulfate, filtered, and concentrated. Purification using
automated flash chromatography (EtOAc/hexanes) was fol-
lowed by evaporation, giving 3p as a white solid (0.19 g, 12%).
TLC Rf 0.5 (50% EtOAc/hexanes). LC−MS (ESI) m/z: 162 [M
+ H]+. 1H NMR (500 MHz, CDCl3) δ 8.47 (br s, 1H), 8.31 (d, J
= 5.7 Hz, 1H), 6.78 (d, J = 5.8 Hz, 1H), 3.84 (s, 3H). 13C NMR
(126 MHz, CDCl3) δ 166.53, 159.99, 158.94, 101.72, 64.25.
4-(Methoxyamino)-N-(3-(pyridin-3-yl)phenyl)pyrimidin-2-
amine (5p). To a mixture of 3p (0.10 mmol, 1.0 equiv) in EtOH
(0.50 mL, 0.20 M) under a nitrogen atmosphere at rt were added
3-(pyridin-3-yl)aniline (0.11 mmol, 1.1 equiv) and a drop of 1 N
HCl. The reaction mixture was heated to reflux and stirred at that
temperature for 3 h; it was then cooled to rt. Purification using
automated flash chromatography (MeOH/DCM) was followed
by evaporation, giving 5p as a colorless oil (0.006 g, 20%). TLC
Rf 0.4 (5% MeOH/DCM). LC−MS (ESI) m/z: 294 [M + H]+.
1H NMR (500 MHz, CDCl3) δ 8.90 (s, 1H), 8.63 (d, J = 5.0 Hz,
1H), 8.24 (d, J = 5.6 Hz, 1H), 7.98−7.86 (m, 2H), 7.61 (s, 1H),
7.56 (d, J = 8.2 Hz, 1H), 7.46−7.34 (m, 2H), 7.27−7.21 (m, 1H),
7.18−7.09 (m, 1H), 6.40 (d, J = 5.6 Hz, 1H), 3.83 (s, 3H). 13C
NMR (126 MHz, CDCl3) δ 166.38, 159.30, 158.40, 148.49,
148.41, 140.30, 138.54, 136.70, 134.44, 129.54, 123.53, 121.14,
118.95, 117.94, 95.89, 64.15.
tert-Butyl 4-((2-chloropyrimidin-4-yl)amino)piperidine-1-
carboxylate (3q). To a suspension of 2,4-dichloropyrimidine 2
(5.0 mmol, 1.0 equiv) in DCM (10mL, 0.50M) under a nitrogen
atmosphere was added 1-Boc-4-aminopiperidine (7.5 mmol, 1.5
equiv) at rt. After stirring for 5 h the reaction mixture was
concentrated. Purification using automated flash chromatog-
raphy (EtOAc/hexanes) was followed by evaporation, giving 3q
as a white foam (0.41 g, 26%). TLC Rf 0.10 (30% EtOAc/
hexanes). LC−MS (ESI) m/z: 313 [M + H]+. 1H NMR (400
MHz, MeOD) δ 7.85 (br s, 1H), 6.40 (br s, 1H), 4.03−4.13 (m,
3H), 2.99 (s, 2H), 2.06−1.89 (m, 2H), 1.48 (s, 9H), 1.45−1.35
(m, 2H). 13C NMR (101 MHz, MeOD) δ 164.55, 161.59,
156.45, 155.77, 105.96, 101.41, 81.17, 43.88, 32.45, 28.68.
tert-Butyl 4-((2-((3-(pyridin-3-yl)phenyl)amino)pyrimidin-
4-yl)amino)piperidine-1-carboxylate (3r). To a mixture of 3q
(0.10 mmol, 1.0 equiv) in EtOH (0.50 mL, 0.20 M) under a
nitrogen atmosphere at rt were added 3-(pyridin-3-yl)aniline
(0.11 mmol, 1.1 equiv) and a drop of 1 N HCl. The reaction
mixture was heated to reflux and stirred at that temperature for 3
h; it was then cooled to rt. Purification using automated flash
chromatography (MeOH/DCM) was followed by evaporation,
giving 3r as a colorless oil (0.007 g, 16%). TLC Rf 0.5 (10%
MeOH/DCM). LC−MS (ESI) m/z: 447 [M + H]+. 1H NMR
(500 MHz, MeOD) δ 8.82 (s, 1H), 8.53 (d, J = 5.0 Hz, 1H),
8.19−8.05 (m, 2H), 7.77 (s, 1H), 7.59 (d, J = 7.4 Hz, 1H), 7.54
(dd, J = 7.9, 4.9 Hz, 1H), 7.42 (t, J = 7.9 Hz, 1H), 7.31−7.16 (m,
1H), 5.97 (d, J = 5.9 Hz, 1H), 4.02 (s, 1H), 3.98−3.84 (m, 2H),
2.60−2.69 (m, 2H), 1.99−1.90 (m, 2H), 1.47 (s, 9H), 1.40−1.28
(m, 2H). 13C NMR (126 MHz, MeOD) δ 162.35, 159.45,
154.98, 153.44, 147.35, 147.11, 141.31, 137.87, 137.60, 135.29,
129.05, 124.10, 120.17, 119.14, 117.92, 97.70, 79.69, 53.40,
42.05, 31.26, 27.27.
N4-(Piperidin-4-yl)-N2-(3-(pyridin-3-yl)phenyl)pyrimidine-
2,4-diamine (5q). To 3r (0.020 mmol, 1.0 equiv) in DCM (1.0
mL, 0.20 M) under a nitrogen atmosphere at rt was added
trifluoroacetic acid (0.20 mmol, 10 equiv). The reaction mixture
was stirred at rt for 3 h and then concentrated. Purification using
automated reversed-phase flash chromatography (water/
MeOH) was followed by evaporation, giving 5q as a colorless
oil (0.007 g, 100%). LC−MS (ESI) m/z: 347 [M + H]+. 1H
NMR (500 MHz, MeOD) δ 8.91 (s, 1H), 8.63 (s, 1H), 8.16 (d, J
= 7.9Hz, 1H), 8.02 (s, 1H), 7.80 (s, 1H), 7.61 (d, J = 8.3Hz, 2H),
7.52 (t, J = 7.8 Hz, 1H), 7.43 (d, J = 7.7 Hz, 1H), 6.15 (d, J = 6.2
Hz, 1H), 4.16−4.20 (m, 1H), 3.35−3.39 (m, 2H), 3.00−2.81 (m,
2H), 2.22−2.26 (m, 2H), 1.84−1.70 (m, 2H). 13C NMR (126
MHz, MeOD) δ 165.13, 162.56, 161.59, 156.29, 147.68, 147.00,
139.44, 137.92, 135.19, 129.43, 124.45, 122.05, 120.74, 119.38,
98.25, 45.38, 42.46, 27.85.
2-Chloro-N-(tetrahydro-2H-pyran-4-yl)pyrimidin-4-amine
(3s). To a suspension of 2,4-dichloropyrimidine 2 (2.5 mmol, 1.0
equiv) in DCM (5.0 mL, 0.50 M) under a nitrogen atmosphere
was added 4-aminotetrohydropyran (5.0 mmol, 2.0 equiv) at rt.
After stirring for 16 h, the reaction mixture was concentrated.
Purification using automated flash chromatography (EtOAc/
hexanes) was followed by evaporation, giving 3s as a white solid
(0.19 g, 35%). TLC Rf 0.30 (70% EtOAc/hexanes). LC−MS
(ESI)m/z: 216 [M +H]+. 1H NMR (500MHz, CDCl3) δ 8.12−
7.94 (m, 1H), 6.25 (d, J = 5.9 Hz, 1H), 5.01 (br s, 1H), 4.00−4.04
(m, 2H), 3.53−3.59 (m, 2H), 2.11−1.96 (m, 2H), 1.63−1.49 (m,
2H). 13C NMR (126 MHz, CDCl3) δ 162.63, 160.99, 157.11,
66.47, 47.24, 32.83.
N2-(3-(Pyridin-3-yl)phenyl)-N4-(tetrahydro-2H-pyran-4-yl)-
pyrimidine-2,4-diamine (5r). To a mixture of 3s (0.094 mmol,
1.0 equiv) in EtOH (0.50 mL, 0.19 M) under a nitrogen
atmosphere at rt were added 3-(pyridin-3-yl)aniline (0.103
mmol, 1.1 equiv) and a drop of 1 N HCl. The reaction mixture
was heated to reflux and stirred at that temperature for 4 h; it was
then cooled to rt. Purification using automated flash chromatog-
raphy (MeOH/DCM) was followed by evaporation, giving 5r as
a colorless oil (0.005 g, 15%). TLC Rf 0.6 (10% MeOH/DCM).
LC−MS (ESI) m/z: 348 [M + H]+. 1H NMR (500 MHz,
CDCl3) δ 8.80 (s, 1H), 8.53 (d, J = 5.1 Hz, 1H), 7.94−7.84 (m,
2H), 7.82 (d, J = 8.0 Hz, 1H), 7.53−7.43 (m, 1H), 7.35−7.27 (m,
2H), 7.23 (s, 1H), 7.13 (dd, J = 7.7, 1.6 Hz, 1H), 5.80 (d, J = 5.8
Hz, 1H), 4.66 (s, 1H), 3.91 (br s, 1H), 3.86 (d, J = 11.5 Hz, 2H),
3.28 (t, J = 11.7 Hz, 2H), 1.93 (d, J = 10.0 Hz, 2H), 1.54−1.35
(m, 2H). 13CNMR (126MHz, CDCl3) δ 161.92, 159.68, 155.79,
148.51, 148.43, 140.74, 138.52, 136.95, 134.46, 129.43, 123.53,
120.84, 118.81, 117.87, 97.05, 66.64, 47.19, 33.17.
N2-([1,1′-Biphenyl]-2-yl)-N4-isopropylpyrimidine-2,4-dia-
mine (6a). To a mixture of 3f (0.10 mmol, 1.0 equiv) in EtOH
(0.50 mL, 0.20 M) under a nitrogen atmosphere at rt were added
2-aminobiphenyl (0.15 mmol, 1.5 equiv) and a drop of 1 N HCl.
The reaction mixture was heated to reflux and stirred at that
temperature for 2 h; it was then cooled to rt. Purification using
automated flash chromatography (MeOH/DCM) was followed
by evaporation, giving 6a as a white solid (0.021 g, 69%). TLC Rf
0.7 (10%MeOH/DCM). LC−MS (ESI)m/z: 305 [M +H]+. 1H
NMR (400 MHz, CDCl3) δ 8.22 (d, J = 8.2 Hz, 1H), 7.71 (d, J =
5.9 Hz, 1H), 7.40−7.33 (m, 4H), 7.31−7.24 (m, 2H), 7.17 (d, J =
1.7 Hz, 1H), 7.03 (td, J = 7.4, 1.2 Hz, 1H), 5.73 (d, J = 6.0 Hz,
1H), 4.84 (br s, 1H), 3.86 (br s, 1H), 1.15 (d, J = 6.4 Hz, 6H). 13C
NMR (101 MHz, CDCl3) δ 162.03, 158.76, 138.82, 136.31,
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N2-(3-(tert-Butyl)phenyl)-N4-isopropylpyrimidine-2,4-dia-
mine (6b). To a mixture of 3f (0.15 mmol, 1.0 equiv) in EtOH
(0.50 mL, 0.30 M) under a nitrogen atmosphere at rt were added
3-(tert-butyl)aniline (0.22 mmol, 1.5 equiv) and a drop of 1 N
HCl. The reaction mixture was heated to reflux and stirred at that
temperature for 1 h; it was then cooled to rt. Purification using
automated flash chromatography (MeOH/DCM) was followed
by evaporation, giving 6b as a colorless oil (0.027 g, 65%). TLC
Rf 0.6 (10%MeOH/DCM). LC−MS (ESI) m/z: 285 [M + H]+.
1H NMR (500 MHz, CDCl3) δ 8.74 (br s, 1H), 7.63 (d, J = 31.1
Hz, 2H), 7.47 (d, J = 8.0Hz, 1H), 7.35−7.22 (m, 2H), 7.14 (d, J =
7.9 Hz, 1H), 6.05 (d, J = 6.5 Hz, 1H), 4.23 (br s, 1H), 1.35 (d, J =
2.0 Hz, 9H), 1.30 (d, J = 8.0 Hz, 6H). 13C NMR (126 MHz,
CDCl3) δ 161.95, 152.02, 137.97, 128.41, 120.65, 117.70, 117.59,
43.36, 34.77, 31.32, 22.53.
N2-([1,1′-Biphenyl]-3-yl)-N4-isopropylpyrimidine-2,4-dia-
mine (6c). To a mixture of 3f (0.10 mmol, 1.0 equiv) in EtOH
(0.50 mL, 0.20 M) under a nitrogen atmosphere at rt were added
3-aminobiphenyl (0.15 mmol, 1.5 equiv) and a drop of 1 N HCl.
The reaction mixture was heated to reflux and stirred at that
temperature for 2 h; it was then cooled to rt. Purification using
automated flash chromatography (MeOH/DCM) was followed
by evaporation, giving 6c as a gray solid (0.020 g, 66%). TLC Rf
0.7 (10%MeOH/DCM). LC−MS (ESI)m/z: 305 [M +H]+. 1H
NMR (400 MHz, chloroform-d) δ 7.81 (d, J = 8.3 Hz, 2H),
7.56−7.47 (m, 3H), 7.43 (d, J = 11.1 Hz, 1H), 7.35 (td, J = 8.2,
7.7, 1.7 Hz, 2H), 7.31−7.23 (m, 2H), 7.15 (dt, J = 7.7, 1.5 Hz,
1H), 5.76 (dd, J = 6.0, 1.3 Hz, 1H), 4.73 (br s, 1H), 4.01 (br s,
1H), 1.17 (d, J = 8.0 Hz, 6H). 13C NMR (101 MHz, CDCl3) δ
162.12, 159.25, 141.92, 141.38, 140.27, 129.09, 128.62, 127.23,
121.03, 118.25, 118.12, 42.89, 22.80.
N4-Isopropyl-N2-(3-(pyridin-2-yl)phenyl)pyrimidine-2,4-di-
amine (6d). To a mixture of 3f (0.14 mmol, 1.0 equiv) in EtOH
(0.50 mL, 0.28 M) under a nitrogen atmosphere at rt were added
3-(2-pyridyl)aniline (0.15 mmol, 1.1 equiv) and a drop of 1 N
HCl. The reaction mixture was heated to reflux and stirred at that
temperature for 3 h; it was then cooled to rt. Purification using
automated flash chromatography (MeOH/DCM) was followed
by evaporation, giving 6d as a colorless oil (0.014 g, 33%). TLC
Rf 0.5 (10%MeOH/DCM). LC−MS (ESI) m/z: 306 [M + H]+.
1H NMR (400 MHz, MeOD) δ 8.64 (d, J = 4.9 Hz, 1H), 8.36 (s,
1H), 7.99−7.83 (m, 2H), 7.67−7.70 (m, 2H), 7.64−7.54 (m,
1H), 7.49 (t, J = 7.9 Hz, 1H), 7.45−7.31 (m, 1H), 6.09 (d, J = 6.7
Hz, 1H), 4.33 (br s, 1H), 1.24 (d, J = 6.5 Hz, 6H). 13CNMR (101
MHz, MeOD) δ 163.57, 158.73, 150.33, 141.35, 140.40, 138.91,
130.44, 123.95, 123.43, 122.73, 122.69, 120.88, 101.41, 44.04,
22.46.
N4-Isopropyl-N2-(3′-methoxy-[1,1′-biphenyl]-3-yl)-
pyrimidine-2,4-diamine (6e). To a mixture of 3f (0.070 mmol,
1.0 equiv) in EtOH (0.50 mL, 0.14 M) under a nitrogen
atmosphere at rt were added (3′-methoxybiphenyl-3-yl)amine
HCl salt (0.084 mmol, 1.2 equiv) and a drop of 1 N HCl. The
reaction mixture was heated to reflux and stirred at that
temperature for 16 h; it was then cooled to rt. Purification using
automated flash chromatography (MeOH/DCM) was followed
by evaporation, giving 6e as a colorless oil (0.013 g, 56%). TLCRf
0.2 (50% EtOAc/hexanes + 1% MeOH). LC−MS (ESI) m/z:
335 [M + H]+. 1H NMR (400 MHz, CDCl3) δ 8.09−7.88 (m,
2H), 7.74−7.63 (m, 2H), 7.53−7.40 (m, 2H), 7.40−7.27 (m,
3H), 7.07−6.92 (m, 1H), 5.96 (d, J = 8.0 Hz, 1H), 4.95 (d, J = 7.8
Hz, 1H), 4.21 (br s, 1H), 3.89 (s, 3H), 1.36 (d, J= 8.0 Hz, 6H).
13C NMR (126 MHz, CDCl3) δ 162.10, 159.86, 159.03, 146.68,
142.90, 141.79, 140.14, 129.60, 129.08, 121.13, 119.76, 118.45,
118.20, 113.08, 112.58, 96.25, 55.31, 42.97, 22.76.
Methyl 3′-((4-(isopropylamino)pyrimidin-2-yl)amino)-
[1,1′-biphenyl]-3-carboxylate (6f). To a mixture of 3f (0.12
mmol, 1.0 equiv) in MeOH (0.50 mL, 0.23 M) under a nitrogen
atmosphere at rt were added 3′-amino-biphenyl-3-carboxylic
acid methyl ester HCl (0.13 mmol, 1.1 equiv) and a drop of 1 N
HCl. The reaction mixture was heated to reflux and stirred at that
temperature for 3 h; it was then cooled to rt. The reaction
mixture was diluted with EtOAc (3 mL) and then washed
sequentially with 1 NHCl (3 mL) and brine (3 mL). The organic
phase was dried over magnesium sulfate and concentrated.
Purification using automated flash chromatography (MeOH/
DCM) was followed by evaporation, giving 6f as a white solid
(0.015 g, 36%). TLC Rf 0.6 (10%MeOH/DCM). LC−MS (ESI)
m/z: 363 [M + H]+. 1H NMR (400 MHz, CDCl3) δ 8.30 (d, J =
1.9 Hz, 1H), 8.05−7.87 (m, 3H), 7.80 (dt, J = 8.0, 1.4 Hz, 1H),
7.62−7.52 (m, 1H), 7.50 (t, J = 7.7 Hz, 1H), 7.38 (t, J = 7.9 Hz,
1H), 7.26−7.19 (m, 1H), 7.09 (s, 1H), 5.83 (d, J = 5.8 Hz, 1H),
4.63 (br s, 1H), 4.05 (br s, 1H), 3.95 (s, 3H), 1.24 (d, J = 6.4 Hz,
6H). 13C NMR (101 MHz, CDCl3) δ 167.08, 162.14, 159.85,
155.96, 141.74, 140.80, 140.73, 131.64, 130.58, 129.24, 128.70,
128.38, 128.31, 120.68, 118.40, 117.81, 52.17, 42.81, 22.82.
N4-Isopropyl-N2-(3-(oxazol-2-yl)phenyl)pyrimidine-2,4-dia-
mine (6g). To a mixture of 3f (0.10 mmol, 1.0 equiv) in EtOH
(0.50 mL, 0.20 M) under a nitrogen atmosphere at rt were added
3-(1,3-oxaxol-2-yl)aniline (0.11 mmol, 1.1 equiv) and a drop of 1
N HCl. The reaction mixture was heated to reflux and stirred at
that temperature for 3 h; it was then cooled to rt. Purification
using automated flash chromatography (MeOH/DCM) was
followed by evaporation, giving 6g as a colorless oil (0.005 g,
17%). TLC Rf 0.5 (10% MeOH/DCM). LC−MS (ESI) m/z:
296 [M+H]+. 1HNMR (500MHz,MeOD) δ 8.66 (t, J = 2.0Hz,
1H), 7.99 (d, J = 0.9 Hz, 1H), 7.88−7.69 (m, 1H), 7.69−7.57 (m,
2H), 7.40 (t, J = 7.9 Hz, 1H), 7.31 (d, J = 0.9 Hz, 1H), 5.96 (d, J =
6.0 Hz, 1H), 4.33 (br s, 1H), 1.27 (d, J = 6.5 Hz, 6H). 13C NMR
(126 MHz, MeOD) δ 162.52, 162.41, 159.55, 153.55, 141.51,
139.19, 128.77, 127.53, 127.10, 120.97, 118.86, 116.51, 97.57,
41.90, 21.44.
N4-Isopropyl-N2-(3-(thiazol-2-yl)phenyl)pyrimidine-2,4-di-
amine (6h). To a mixture of 3f (0.10 mmol, 1.0 equiv) in EtOH
(0.50 mL, 0.20 M) under a nitrogen atmosphere at rt were added
3-(1,3-thiazol-2-yl)aniline (0.11 mmol, 1.1 equiv) and a drop of 1
N HCl. The reaction mixture was heated to reflux and stirred at
that temperature for 3 h; it was then cooled to rt. Purification
using automated flash chromatography (MeOH/DCM) was
followed by evaporation, giving 6h as a colorless oil (0.004 g,
13%). TLC Rf 0.5 (10% MeOH/DCM). LC−MS (ESI) m/z:
312 [M+H]+. 1HNMR (500MHz,MeOD) δ 8.53 (t, J = 2.1Hz,
1H), 7.87 (d, J = 3.3 Hz, 1H), 7.83−7.68 (m, 1H), 7.68−7.58 (m,
2H), 7.54 (d, J = 10.0 Hz, 1H), 7.38 (t, J = 7.9 Hz, 1H), 5.96 (d, J
= 6.0 Hz, 1H), 4.35 (br s, 1H), 1.25 (d, J = 6.5 Hz, 6H). 13CNMR
(126 MHz, MeOD) δ 169.29, 162.43, 159.55, 153.50, 142.90,
141.60, 133.43, 128.90, 120.62, 119.18, 116.81, 97.61, 41.85,
21.44.
N2-(3-(1H-Pyrazol-3-yl)phenyl)-N4-isopropylpyrimidine-
2,4-diamine (6i). To a mixture of 3f (0.10 mmol, 1.0 equiv) in
EtOH (0.50 mL, 0.20M) under a nitrogen atmosphere at rt were
added 3-(1H-pyrazol-3-yl)aniline (0.11 mmol, 1.1 equiv) and a
drop of 1 N HCl. The reaction mixture was heated to reflux and
stirred at that temperature for 3 h; it was then cooled to rt.
Purification using automated flash chromatography (MeOH/
DCM) was followed by evaporation, giving 6i as a white oil
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(0.020 g, 68%). TLC Rf 0.3 (10%MeOH/DCM). LC−MS (ESI)
m/z: 295 [M + H]+. 1H NMR (500 MHz, MeOD) δ 8.12 (br s,
1H), 7.81−7.71 (m, 1H), 7.67 (br s, 1H), 7.61−7.54 (m, 1H),
7.31−7.38 (m, 2H), 6.65 (br s, 1H), 5.94 (d, J = 6.1 Hz, 1H), 4.26
(br s, 1H), 1.24 (d, J = 6.5 Hz, 6H). 13C NMR (126 MHz,
MeOD) δ 162.44, 159.53, 153.19, 151.87, 140.94, 133.84,
129.47, 128.57, 118.84, 116.64, 101.95, 97.35.
N2-(3-(1H-Imidazol-1-yl)phenyl)-N4-isopropylpyrimidine-
2,4-diamine (6j). To a mixture of 3f (0.10 mmol, 1.0 equiv) in
EtOH (0.50 mL, 0.20M) under a nitrogen atmosphere at rt were
added 3-(1H-imidazol-1-yl)aniline (0.11 mmol, 1.1 equiv) and a
drop of 1 N HCl. The reaction mixture was heated to reflux and
stirred at that temperature for 6 h; it was then cooled to rt.
Purification using automated flash chromatography (MeOH/
DCM) and then reversed-phase chromatography (MeCN/
water) was followed by evaporation, giving 6j as a colorless oil
(0.004 g, 14%). LC−MS (ESI) m/z: 295 [M + H]+. 1H NMR
(500 MHz, MeOD) δ 8.28 (br s, 1H), 8.15 (br s, 1H), 7.75 (br s,
2H), 7.54−7.56 (m, 1H), 7.48 (t, J = 8.0 Hz, 1H), 7.45−7.09 (m,
2H), 6.07 (d, J = 5.8 Hz, 1H), 4.24 (br s, 1H), 1.25 (d, J = 6.5 Hz,
6H). 13C NMR (126 MHz, MeOD) δ 162.22, 156.66, 147.86,
140.93, 137.76, 129.90, 118.82, 115.17, 112.80, 98.35, 42.50,
21.05.
N4-Isopropyl-N2-(3-(pyrazin-2-yl)phenyl)pyrimidine-2,4-di-
amine (6k). To a mixture of 3f (0.10 mmol, 1.0 equiv) in EtOH
(0.50 mL, 0.20 M) under a nitrogen atmosphere at rt were added
3-(pyrazin-2-yl)aniline (0.11 mmol, 1.1 equiv) and a drop of 1 N
HCl. The reaction mixture was heated to reflux and stirred at that
temperature for 3 h; it was then cooled to rt. Purification using
automated flash chromatography (MeOH/DCM) was followed
by evaporation, giving 6k as a colorless foam (0.011 g, 36%).
TLC Rf 0.5 (10%MeOH/DCM). LC−MS (ESI)m/z: 307 [M +
H]+. 1H NMR (500 MHz, MeOD) δ 9.09 (d, J = 1.5 Hz, 1H),
8.68 (dd, J = 2.6, 1.6 Hz, 1H), 8.63 (s, 1H), 7.74 (br s, 1H), 7.70−
7.61 (m, 2H), 7.43 (t, J = 7.9 Hz, 1H), 5.95 (d, J = 6.0 Hz, 1H),
4.45−4.17 (m, 1H), 1.25 (d, J = 6.5 Hz, 6H). 13C NMR (126
MHz, MeOD) δ 162.41, 159.46, 153.34, 144.14, 142.44, 141.78,
141.45, 136.42, 128.86, 120.48, 119.72, 117.46, 97.33, 41.84,
21.43.
N4-isopropyl-N2-(3-(pyridin-4-yl)phenyl)pyrimidine-2,4-di-
amine (6l). To a mixture of 3f (0.10 mmol, 1.0 equiv) in EtOH
(0.50 mL, 0.20 M) under a nitrogen atmosphere at rt were added
3-(4-pyridyl)aniline (0.11 mmol, 1.1 equiv) and a drop of 1 N
HCl. The reaction mixture was heated to reflux and stirred at that
temperature for 3 h; it was then cooled to rt. Purification using
automated flash chromatography (MeOH/DCM) was followed
by evaporation, giving 6l as an orange solid (0.002 g, 7%). TLC Rf
0.5 (10%MeOH/DCM). LC−MS (ESI)m/z: 306 [M +H]+. 1H
NMR (500 MHz, CDCl3) δ 8.74−8.59 (m, 2H), 8.07 (br s, 1H),
7.95 (d, J = 5.7 Hz, 1H), 7.64−7.58 (m, 1H), 7.58−7.51 (m, 2H),
7.43 (t, J = 7.9 Hz, 1H), 7.27 (s, 1H), 7.14 (br s, 1H), 5.88 (d, J =
5.8 Hz, 1H), 4.69 (br s, 1H), 4.10 (br s, 1H), 1.28 (d, J = 6.5 Hz,
6H). 13C NMR (126 MHz, CDCl3) δ 162.12, 159.56, 155.58,
150.15, 148.67, 140.88, 138.85, 129.48, 121.79, 120.44, 119.58,
117.51, 42.79, 22.85.
N2-([1,1′-Biphenyl]-4-yl)-N4-isopropylpyrimidine-2,4-dia-
mine (6m). To a mixture of 3f (0.12 mmol, 1.0 equiv) in EtOH
(0.50 mL, 0.23 M) under a nitrogen atmosphere at rt were added
4-aminobiphenyl (0.18 mmol, 1.5 equiv) and a drop of 1 N HCl.
The reaction mixture was heated to reflux and stirred at that
temperature for 2 h; it was then cooled to rt. Purification using
automated flash chromatography (MeOH/DCM) was followed
by evaporation, giving 6m as a white solid (0.024 g, 68%). TLC Rf
0.7 (10%MeOH/DCM). LC−MS (ESI)m/z: 305 [M +H]+. 1H
NMR (400 MHz, chloroform-d) δ 8.05 (br s, 1H), 7.81 (br s,
1H), 7.73−7.63 (m, 2H), 7.63−7.48 (m, 4H), 7.48−7.37 (m,
2H), 7.34−7.28 (m, 1H), 5.93 (d, J = 6.2 Hz, 1H), 5.34 (br s,
1H), 4.07 (br s, 1H), 1.28 (d, J = 6.5 Hz, 6H). 13C NMR (101
MHz, CDCl3) δ 162.08, 140.77, 138.57, 135.42, 128.73, 127.41,
126.81, 126.72, 119.93, 43.25, 22.64.
4-((4-(Isopropylamino)pyrimidin-2-yl)amino)benzamide
(6n). To a mixture of 3f (0.10 mmol, 1.0 equiv) in EtOH (0.50
mL, 0.20 M) under a nitrogen atmosphere at rt were added 4-
aminobenzamide (0.15 mmol, 1.5 equiv) and a drop of 1 N HCl.
The reaction mixture was heated to reflux and stirred at that
temperature for 2 h; it was then cooled to rt. Purification using
automated flash chromatography (MeOH/DCM) was followed
by evaporation, giving 6n as a white solid (0.013 g, 48%). TLC Rf
0.3 (10%MeOH/DCM). LC−MS (ESI)m/z: 272 [M +H]+. 1H
NMR (500 MHz, MeOD) δ 7.86−7.77 (m, 5H), 5.99 (d, J = 6.1
Hz, 1H), 4.23 (s, 1H), 1.27 (d, J = 6.5 Hz, 6H). 13C NMR (126
MHz, MeOD) δ 170.82, 162.40, 159.20, 153.30, 144.38, 128.12,
125.46, 117.72, 97.87, 41.96, 21.31.
Biology. Biochemical Assays. Briefly, kinase reactions were
conducted in triplicate, with a final assay volume of 10 μL, in
black polystyrene 384-well plates (Corning #8849BC) using the
Z′-LYTE Kinase Assay Kit (Tyr 2 peptide; Life Technologies).
The reaction mixtures contained 500 μM ATP, 2 μM Tyr 2
peptide, and 6.25 or 12.50 nM recombinant human FLT3 (571−
993 (SignalChem) in buffer [50 mM HEPES (pH 7.5), 10 mM
MgCl2, 1 mMEGTA, 0.01% Brij-35, 0.25 mMDTT]). A cocktail
of FLT3, ATP, and peptide solution prepared in the above-
described buffer (10 μL) was added to the plates using an
automated plate filler (Wellmate, Matrix). DMSO stock
solutions of the test compounds were then added in a dilution
series by pin transfer (V&P Scientific) in nanoliter volumes. After
1 h of incubation at 23 °C, the reaction mixtures were quenched
and processed according to the Z′-LYTE kit protocol and read on
an automated EnVision (Perkin-Elmer) plate reader using a 400
nm excitation filter and a 535 nm emission filter. Fluorescence
emission ratio data were processed using a custom script written
in Pipeline Pilot (Accelrys) to transform data by log10 and
calculate percent inhibition normalized in comparison to the
means of positive and negative controls. Dose−response curves
were plotted using GraphPad Prism software.
MV4-11 and BJ Cell Culture and Cytotoxicity Studies. BJ and
MV4-11 cells were purchased from the American Type Culture
Collection (ATCC, Manassas, Virginia). The cells were cultured
in a humidified 5% CO2 incubator at 37 °C according to vendor
recommendations. BJ cells are cultured in EMEM media and
MV4-11 cells are cultured in IMDM media purchased from
ATCC; both lines are supplemented with 10% fetal bovine serum
(GE Healthcare Life Sciences, Hyclone Laboratories, Logan,
Utah). The cells were routinely tested for mycoplasma with the
MycoAlert Mycoplasma Detection Kit (Lonza, Walkersville,
MD).
Approximately 1000 BJ or 500 MV4-11 exponentially growing
cells were plated per well (30 μL) in white polystyrene flat-
bottom sterile 384-well tissue-culture-treated plates (Corning,
Tewksbury, MA) and incubated overnight at 37 °C in a
humidified 5% CO2 incubator. Compound solutions (DMSO)
were pin-transferred (V&P Scientific, San Diego, CA) the
following day. Inhibition of proliferation was determined
following 72 h of incubation using Promega Cell Titer Glo
Reagent according to the manufacturer’s recommendations.
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Luminescence was measured on an Envision plate reader
(Perkin-Elmer).
MOLM13 Cell Culture. Parental MOLM13FLT3‑ITD cells
harboring FLT3-ITD (DSMZ, Brunswick, Germany) and
MOLM13FLT3‑ITD/D835Y cells carrying an additional D835Y
mutation were maintained in RPMI 1640medium supplemented
with 10% fetal bovine serum (Life Technologies, Grand Island,
NY) in a humidified 5% CO2 incubator at 37 °C.
9,50 The
MOLM13FLT3‑ITD/D835Ycells were maintained in the presence of
5μM tandutinib (LC Laboratories, Woburn, MA) and removed
from the presence of the drug 3 days prior to experimentation
MOLM13 Cell Viability. Cell viability upon drug treatment
was assessed using the MTT reagent (Roche Applied Science,
Indianapolis, IN), as previously described.50 Briefly, the cells
were plated overnight in a humidified 5% CO2 incubator at 37
°C. On day 2, the cells were treated with DMSO or drug
reconstituted in DMSO for 72 h. The drug concentrations used
were as follows: compound 1, 1000−167 nM; compound 5e
1600−6.55 nM; compound 6a, 1000−6.55 nM; and compound
6k, 1500−0.98 nM. Three individual experiments were
conducted, with six replicates each. Cell viability was quantified
as relative percentage to DMSO-treated cells, and cell viability
curves were generated using GraphPad Prism software version
6.07.
Western Blot Analysis. Whole-cell lysates were made with
radioimmunoprecipitation assay buffer (20 mM Tris−HCl (pH
7.5), 150 mMNaCl, 1 mMNa2EDTA, 1 mM EGTA, 1% NP-40,
1% sodium deoxycholate, 0.1% SDS, and protease and
phosphatase inhibitors). Immunoprecipitation was carried out
with anti-FLT3 antibody and Protein A/G agarose beads from
Santa Cruz Biotechnology (Dallas, TX). Invitrogen Bis−tris-
gradient mini or midi gels were used for western blot analysis,
followed by detection with enhanced chemiluminescence (ECL)
reagent. Primary antibodies used were from Cell Signaling
Technology (Danvers, MA): FLT3, phospho-FLT3, STAT5,
and phospho-STAT5. Secondary antibodies were from Jackson
Immunoresearch and Cell Signaling Technology.
In Vivo Pharmacokinetic Study. All animal studies were
carried out under a St Jude Children’s Research Hospital
IACUC-approved protocol (#477). Female C57BL/6 mice, with
an average weight of 18 g, were purchased from Charles River
Laboratories (Wilmington, MA). Food and water were provided
ad libitum. Twenty-four mice were divided into four dosage
groups: 0, 3, 5, and 10 mg/kg. For each mouse, 0.1 mL of the
compound suspension in formulation (5:50:45, EtOH/
PEG400/PBS (pH 7.4), v/v/v) was administered by i.p.
injection. Blood (0.1 mL) was collected retro-orbitally from a
different mouse within each dosage group at 5, 15, and 30 min
and 1, 4, and 24 h. The animals were euthanized via cardiac
puncture after anesthesia at 48 h post injection. The blood
samples were treated with 10 μL of EDTA sodium solution to
prevent coagulation. The blood samples were kept under ice and
centrifuged for 3 min at 13 200 rpm in a desktop centrifuge to
collect plasma. The plasma samples (25 μL) were combined with
75 μL of internal standard (2 μMwarfarin) in acetonitrile in a 96-
well plate and centrifuged at 4000 rpm for 20 min at 4 °C. The
supernatant (40 μL) was collected and mixed with two parts of
deionized water and centrifuged again at 4000 rpm for 20 min at
4 °C. The plasma concentration was determined using an LC/
MS−MS assay with multiple reaction monitoring detection (AB
Sciex, Framingham, MA). The LC/MS−MSmethod is provided
in the Supporting Information. The assay limit of quantification
(LLOQ) was 13.7 nM in plasma.
The processed plasma concentration−time data were analyzed
using noncompartmental analysis (NCA) inWinNonlin 6.0 with
the Plasma (200−202)model type; all standard NCA parameters
were estimated via default software settings, using predicted
parameter estimates. If at least two-thirds of the observed
concentrations were below the LLOQ, the mean concentration
was treated as missing.
The AUC was calculated with the linear trapezoidal, linear
interpolation rule using mean concentrations and nominal times.
The terminal elimination rate (Lambda_z) and half-life
(HL_Lambda_z) were determined using the default “Best Fit”
method. The predicted AUC from the last time point to infinity
(AUCINF_pred) was calculated as AUClast plus Clast(pred)/
Lambda_z. CL was calculated as Dose/AUCINF_pred.
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